BIOLOGICALLY ACTIVE AMINES

Abstract: There are disclosed compounds of the formula (I): Ar-CH2CH2-NH-CR<1>R<2>-X-Y in which Ar represents a group alpha , X represents a C1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from -S-, -SO-, -SO2-, -O-, CR<6>R<7>, phenylmethyne, -NH-, -CONH-, -NHCO- and -NHCONH-, Y represents an optionally substituted aryl or cycloalkyl group, R<1>, R<2>, R<5>, R<6>, R<7> and R<8> each independently represent hydrogen or alkyl C1-6, and R<3> and R<4> represent hydrogen, or R<3> and R<4> together form a group -S-, -NR<8>- or -CH2-, and pharmaceutically acceptable derivatives thereof. Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.

Description: Biologically Active Amines This invention relates to novel compounds, processes for their preparation, compositions containing them and methods of treatment involving their use. According to the invention there are provided compounds of formula I, Ar-CH 2 CH 2 -NH-CR 1 !. 2 -X-Y in which Ar represents a group. X represents a C 1 _ 12 al ylene chain optionally interrupted or terminated by one or more groups selected from -S-, -SO-, -S0 2 -, -0-, CR 6 R , phenylmethyne, -NH-, -CONH-, -NHCO- and -NHCONH-, Y represents an optionally substituted aryl or cycloalkyl group, R 1 , R 2 , R 5 , R 6 , R 7 and R 8 each independently represent hydrogen or alkyl C^g, and R 3 and R 4 represent hydrogen, or R 3 and R 4 together form a group -S-, -NR 8 - or -CH 2 ~, and and pharmaceutically acceptable derivatives thereof. According to the invention we also provide a process for the production of a compound of formula I, or a pharmaceutically acceptable derivative thereof, which comprises a) alkylation of a compound of formula II, or a derivative thereof. Ar-CH 2 CH 2 -NH 2 II in which Ar is as defined above, with an alkylating agent of formula III, L-CR^-X-Y III in which R 1 , R 2 , X and Y are as defined above and L represents a leaving group, b) alkylation of a compound of formula II, as defined above, with a compound of formula IV, 0=CR 1 -X-Y IV in which R 1 , X and Y are as defined above, in the presence of a reducing agent, c) selective reduction of a compound of formula V, Ar-CH 2 -C-NH-CR 3 -^ 2 -X-Y in which Ar, X, Y, R 1 and R 2 are as defined above, or for the production of compounds of formula I in which R 1 and R 2 represent hydrogen selective reduction of a compound of formula Va, O Ar-CH 2 CH 2 -NH-C-X-Y Va in which Ar, X and Y are as defined above, d) removal of a protecting group from a corresponding protected compound of formula I in which one or more of the functional groups is protected, and where desired or necessary converting the resulting compound of formula I to a pharmaceutically acceptable derivative thereof, or vice versa. In process a) leaving groups which L may represent include halogen, such as chlorine, bromine and iodine, and alkyl or arylsulphonyloxy groups such as methanesulphonyloxy or p-toluenesulphonyloxy. The reaction is preferably carried out in the presence of a base, e.g. an inorganic base such as sodium or potassium carbonate, or an organic base such as triethylamine, N,N-diisopropylethylamine or pyridine. The reaction is conveniently performed in a solvent such as an ether, e.g. tetrahydrofuran or dioxan, a ketone, e.g. butanone or methyl isobutyl ketone, a substituted amide, e.g. dimethylformamide, or a chlorinated hydrocarbon, e.g. chloroform, at a temperature of between ambient temperature and the reflux temperature of the solvent. The alkylating agent of formula III may be prepared from the corresponding alcohol (i.e. the compound in which L represents OH) by known methods. For example, the alcohol may be reacted with a halogenating agent to yield the compound of formula III in which L represents a halogen atom. Suitable halogenating agents include, for example, triphenylphosphine-tetrahalogenomethane adduct (conveniently formed in situ, e.g. by the reaction of triphenylphosphine and carbontetrabromide) . The reaction may take place in the presence of a solvent such as acetonitrile, or a chlorinated hydrocarbon, e.g. dichloromethane, at a temperature in the range of 0-30°C. In process b) suitable reducing agents include hydrogen in the presence of a catalyst such as platinum, platinum oxide, palladium, palladium oxide, Raney nickel or rhodium, on a support such as charcoal, using an alcohol, e.g. ethanol, or an ester, e.g. ethyl acetate, or an ether, e.g. tetrahydrofuran, or water, as reaction solvent, or a mixture of solvents, at normal or elevated temperature and pressure. Alternatively the reducing agent may be a hydride such as diborane or a metal hydride such as sodium borohydride, sodium cyanoborohydride or lithium aluminium hydride. Suitable solvents for the reaction with these reducing agents will depend on the particular hydride used, but will include alcohols, such as methanol or ethanol, or ethers, such as diethyl ether or t-butyl methyl ether, or tetrahydrofuran. Alkylation using the compound of formula IV may give rise to an intermediate imine, reduction of which under the conditions described yields the compound of formula I. The compounds of formulae II and IV and the alcohols corresponding to formula III are either known or may be prepared by known techniques. In process c) the reaction may be carried out using conventional reduction techniques. The reducing agent may be electrophilic, e.g. diborane, or nucleophilic, e.g. a complex metal hydride such as lithium aluminium hydride or sodium bis(2-methoxyethoxy)aluminium hydride. The solvent is preferably inert to the reaction conditions. Aprotic solvents are preferred, e.g. tetrahydrofuran, diethyl ether, or 1,2-dimethoxyethane. The reaction may be carried out at a temperature of from about 0 to 100"C. The compounds of formula V and Va may be prepared by coupling of an a ine and an acid or acid chloride by conventional means. For example, the coupling may be performed in the presence of dicyclohexylcarbodiimide using the method of Sheehan and Hess, J. Am. Chem. Soc.. 1955, 77, 1067; or 1,1-dicarbonyldiimidazole as described by Staab, Anσew. Chem. Int. Ed. Enσl.. 1962, JL, 351. The amines required for the coupling reaction are either known or may be prepared by conventional methods, for example, compounds in which R 3 and R 4 together represent -S- may be prepared as described in J. Med. Chem.. 1987, 2 , 1166. The intermediates of formula Va are novel, thus according to a further aspect of the invention there are provided compounds of formula Va, 0 II Ar-CH 2 CH 2 -NH-C-X-Y Va in which Ar, X and Y are as defined above. Further preparative details for the compounds of formula I are given in the Examples. In the above processes it may be necessary for any functional groups, e.g. hydroxy or amino groups, present in the starting materials to be protected, thus process d) may involve the removal of one or more protecting groups. Suitable protecting groups and methods for their removal are, for example, those described in "Protective Groups in Organic Chemistry" by Theodora Greene, John Wiley and Sons Inc., 1981. Hydroxy groups may, for example, be protected by arylmethyl groups such as phenylmethyl, diphenylmethyl or triphenylmethyl, or as tetrahydropyranyl derivatives. Suitable amino protecting groups include arylmethyl groups such as benzyl, (R,S)-α-phenylethyl, diphenylmethyl or triphenylmethyl, and acyl groups such as acetyl, trichloroacetyl or trifluoroacetyl. Conventional methods of deprotection may be used. Arylmethyl groups may, for example, be removed by hydrogenolysis in the presence of a metal catalyst e.g. palladium on charcoal. Tetrahydropyranyl groups may be cleaved by hydrolysis under acidic conditions. Acyl groups may be removed by hydrolysis with a base such as sodium hydroxide or potassium carbonate, or a group such as trichloroacetyl may be removed by reduction with, for example, zinc and acetic acid. Pharmaceutically acceptable derivatives of the compound of formula I include pharmaceutically acceptable salts, esters and amides thereof. Suitable pharmaceutically acceptable salts of the compounds of formula I include acid addition salts derived from inorganic and organic acids, such as hydrochlorides, hydrobromides, sulphates, phosphates, maleates, tartrates, citrates, benzoates, 4-methoxybenzoates, 2- or 4-hydroxybenzoates, 4-chlorobenzoates, benzenesulphonates, p-toluenesulphonates, naphthalenesulphonates, methanesulphonates, sulphamates, ascorbates, salicylates, acetates, diphenylacetates, triphenylacetates, adipates, fumarates, succinates, lactates, glutarates, gluconates, hydroxy-naphthalenecarboxylates, e.g. 1-hydroxy or 3-hydroxy-2-naphthalenecarboxylates, or oleates. The compounds may also form salts with suitable bases. Examples of such salts include alkali metal, e.g. sodium and potassium, and alkaline earth metal, e.g. calcium and magnesium, salts. The compound of formula I may be obtained in the form of a salt, conveniently a pharmaceutically acceptable salt. Where desired, such salts may be converted to the free bases using conventional methods. Pharmaceutically acceptable salts may be prepared by reacting the compound of formula I with an appropriate acid or base in the presence of a suitable solvent. Suitable pharmaceutically acceptable esters of the compounds of formula I include lower alkyl esters, e.g. ethyl ester. The esters may be made by conventional techniques, e.g. esterification or transesterification. Suitable amides include unsubstituted or mono- or di-substituted alkyl C-^.g or phenyl amides, and may be made by conventional techniques, e.g. reaction of an ester of the corresponding acid with ammonia or an appropriate amine. The compounds of formula I may exhibit tautomeris , they may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. chro atography or fractional crystallisation. The various optical isomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation. By the term alkyl we mean straight, branched or cyclic saturated or unsaturated alkyl groups. The term cycloalkyl includes ~ - 2 C Y C --- C groups. The cycloalkyl group may contain from 1 to 3 heteroatoms selected from N, 0 and S. The cycloalkyl group may be unsubstituted or substituted, for example, by one or more groups selected from -OH, halogen, alkyl C 1-6 , alkoxy -1- Q I =0, -NH or N0 2 . Provided that such substituents do not interfere with the efficacy of the compound. Particular cycloalkyl groups which may be mentioned include C 5 and C 6 cycloalkyl groups, e.g. cyclohexane. The term aryl includes aromatic radicals having five or six atoms in a single ring system, such groups may contain from 1 to 3 heteroatoms selected from N, 0 and S. The single ring system may be substituted to form a multiple fused ring system containing up to 10 atoms, for example, naphthyl, indenyl or benzothiazolyl. The aryl group may be unsubstituted or substituted, for example, by one or more groups selected from -OH, halogen, alkyl c l-6' lkoxv c i-6' =0 ' "" NH 2 or N0 2* Provided that such substituents do not interfere with the efficacy of the compound. Particular aryl groups which may be mentioned include 5 and 6-membered carbocyclic and heterocyclic aryl groups, for example, furanyl, pyridinyi and thienyl. However, we prefer compounds of formula I in which Y represents phenyl. Halogens with which Y may be substituted include bromine, chlorine and fluorine. Where the group X contains more than one group selected from -S-, -SO-, -S0 2 -, -0-, CR 6 R 7 , phenylmethyne, -NH-, -C0NH-, -NHCO- and -NHC0NH-, then those groups may be the same or different. We prefer compounds in which X is interrupted or terminated by at least one group, and more preferably one to three groups, e.g. one or two groups, selected from -S-, -SO-, -S0 2 -, -0-, CR 6 R 7 , phenylmethyne, -NH-, -CONH-, -NHCO- and -NHCONH- Specific groups which X may represent include the following: -(CH 2 ) 2 S0 2 (CH 2 ) 2 0(CH 2 ) 2 - -CH 2 S0 2 (CH 2 ) 3 0(CH 2 ) 2 - -(CH 2 ) 5 0- -(CH 2 ) 5 OCH 2 - -(CH 2 ) 5 0(CH 2 ) 2 - -(CH 2 ) 5 0(CH 2 ) 3 - -(CH 2 ) 5 0(CH 2 ) 4 - -(CH 2 ) 3 0(CH 2 ) 2 - -(CH 2 ) 2 S0 2 (CH 2 ) 2 NH(CH 2 ) 2 - -(CH 2 ) 4 CONH(CH 2 ) 2 - -CH 2 S0 2 (CH 2 ) 2 CONH(CH 2 ) 2 - -(CH 2 ) 5 NHCONH(CH 2 ) 2 - -CHMe(CH 2 ) 4 0(CH 2 ) 2 - -CMe 2 (CH 2 ) 4 0(CH 2 ) 2 - We prefer compounds of formula I in which R 3 and R 4 together represent the group -S-. We prefer Ar groups in which the -OH is positioned ortho to the NH group. When R 1 and R 2 are other than hydrogen, alkyl groups which they may represent include alkyl C 1 _ 3 , for example, methyl. We prefer compounds of formula I in which R represents hydrogen. The compounds of formula I are useful in that they exhibit pharmacological activity in animals. In particular the compounds are 0 2 -adrenoreceptor agonists. The activity may be demonstrated in the isolated trachea of the guinea pig, as described by T.P. Kenakin, Br. J. Pharmacol.. 1980, 21, 407. The compounds are also dopamine DA 2 -agonists. The binding affinities of the test compounds for the DA 2 binding sites in bovine pituitary membranes may be determined from the displacement of [ 3 H]-N-n-propylnorapomorphine and of [ 3 H]-spiperone in the absence or presence of nonhydrolysable GTP analogue respectively, D.R. Sibley, A. DeLean and I. Creese, Anterior Pituitary Dopamine Receptors, Demonstration of Interconvertible High and Low Affinity Sites of the D-2 Dopamine Receptor, J. Biol. Chem.. 1982, 257(11) . 6351-6361. The DA 2 activity may also be demonstrated in a functional screen, the rabbit isolated ear artery. Brown and O'Connor, Br. J. Pharmacol.. 1981, 73., 189P. The compounds also show advantageous DA 2 :/3 2 activity ratios. The compounds of formula I are indicated for use in the treatment of the range of conditions known as reversible obstructive airways disease, e.g. asthma and bronchitis. According to another aspect of the invention there is therefore provided a method of treatment or prophylaxis of reversible obstructive airways disease, which method comprises administering a therapeutically effective quantity of a compound of formula I, or a pharmaceutically acceptable derivative thereof, to a patient suffering from or susceptible to such a condition. The compounds of formula I are also indicated for use in the treatment of various other conditions, e.g. inflammatory and allergic skin disorders, congestive heart failure and glaucoma. For the above mentioned uses the doses administered will, of course, vary with compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compound is administered at a daily dosage of from about 0.1 mg to about 20 mg per kg of animal body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man the total daily dose is in the range of from 7.0 mg to 1,400 mg and unit dosage forms suitable for oral administration comprise from 2.0 mg to 1,400 mg of the compound admixed with a solid or liquid pharmaceutical diluent or carrier. The compounds of formula I may be used on their own or in the form of appropriate medicinal preparations for enteral, parenteral or topical administration. According to the invention there is also provided a pharmaceutical composition comprising preferably less than 80% and more preferably less than 50% by weight of a compound of formula I, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Examples of such adjuvants, diluents and carriers are for tablets and dragees - lactose, starch, talc, stearic acid; for capsules - tartaric acid or lactose; for injectable solutions - water, alcohols, glycerin, vegetable oils; for suppositories - natural or hardened oils or waxes. Compositions in a form suitable for oesophageal administration include tablets, capsules and dragees; compositions in a form suitable for administration to the lung include aerosols, particularly pressurised aerosols; compositions in a form suitable for administration to the skin include creams, e.g. oil-in-water emulsions or water-in-oil emulsions; compositions in a form suitable for administration to the eye include drops and ointments. The compounds of formula I have the advantage that they are less toxic, more efficacious, are longer acting, have a broader range of activity, are more potent, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties, than compounds of similar structure. The invention is illustrated, but in no way limited, by the following Examples, in which temperatures are in degrees Celsius. The reactions were performed under an inert atmosphere of either nitrogen or argon. Example 1 7-r2-f6-f2-(2.3-Dihydro-lH-indenyloxy, ]hexyl " )amino- ethyl1-4-hydroxy-l.3-benzthiazol-2 _3H.-one hydrochloride a) N-f2-.4-Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl.ethyl .- 6-.2-(2.3-dihvdro-lH-indenyloxy, ]hexanamide To a stirred solution of 7-(2-aminoethyl)-4-hydroxy- l,3-benzothiazol-2(3H)-one hydrobromide (1.50 g) and 6-[2-(2,3-dihydro-lH-indenyloxy) ]hexanoic acid (1.41 g) in dimethylformamide (25 ml) was added triethylamine (0.72 ml), 1-hydroxybenzotriazole hydrate (1.905 g) and dicyclohexylcarbodiimide (1.38 g) . The mixture was stirred for 40 hours at room temperature. Glacial acetic acid (0.4 ml) was added and stirring continued for 15 in. The dimethylformamide was removed under reduced pressure, the residue slurried with ethyl acetate (50 ml) and the suspended dicyclohexylurea removed by filtration. The filtrate was washed with saturated aqueous sodium bicarbonate and dried (MgS0 4 ) . The solvent was removed under reduced pressure to yield a residue which was purified by column chromatography on silica using 5% ethanol in dichloromethane as eluant, to give the sub-titled compound as a yellow oil. nmr δ (dgDMSO) 1.22 (m, 2H) , 1.45 (brm, 4H) , 2.00 (t, 2H) , 2.58 (t, 2H) , 2.80 (d, IH) , 2.85 (d, IH) , 3.06 (d, IH) , 3.10 (d, IH) , 3.22 (q, 2H) , 3.4 (m, 2H+H 2 0) , 4.26 (m, IH) , 6.70 (d, IH) , 6.80 (d, IH) , 7.1-7.2 (m, 4H) , 7.83 (t, IH) , 9.88 (brs, IH) , 11.61 (s, IH) . b) 7-f2-r6-r2-f2.3-Dihvdro-lH-indenyloxy_ 1hexyl1amino- ethyl1-4-hvdroxy-l.3-benzthiazol-2.3H_-one hvdrochloride Borane-tetrahydrofuran solution (1.0 M in THF, 11 ml) was added dropwise to a stirred solution of the product from step a) (1.39 g) in dry tetrahydrofuran. The mixture was heated under reflux until thin layer chromatography indicated the reaction had gone to completion, about 3 hours. The reaction was cooled and methanol (2.5 ml) added, the mixture was then heated under reflux for a further 15 min. The solvent was removed under reduced pressure and the residue dissolved in methanol (25 ml) to which wes added cone, hydrochloric acid (sg. 1.18, 0.55 ml) . Ti_e solution was heated under reflux for 30 min. Cooling and removal of the methanol under reduced pressure yielded an oily residue which when triturated with ether gave the title compound as an off white solid, which was further purified by reverse phase HPLC using methanol/0.1% aqueous crifluoroacetate as eluant. mp 220-223" ; Mass Spectrum: FAB 427 ((M+H) + ); nmr δ (dgDMSO) 1.23 (brs, 4H) , 1.48 (brt, 2H) , 1.59 (brm, 2H) , 2.85 (brm, 6H) , 3.10 (brm, 4H) , 3.42 (t, 2H) , 4.26 (m, IH) , 6.76 (d, IH) , 6.86 (d, IH) , 7.12 (m, 2H) , 7.20 (m, 2H) , 8.80 (brs, 2H) , 10.13 (s, IH) , 11.77 (s, IH) ; Analysis : Found C, 61.94 ; H, 6.91 ; N, 6.15 ; S , 6.52% C 24 H 30 N 0 3 S .HC1 requires : C, 62.25; H, 6.75 ; N, 6.05 ; S , 6.92% . Example 2 The following compounds were prepared according to the method of Example 1, from the corresponding intermediate amides: --■) 4-Hvdroxy-7-r2-r6-.2-phenylethoxy)hexy1 ]aminoethyl1- l,3-benzothiazol-2 (3Hl-one hvdrochloride i. N-r2-(4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl1-6 - (2-phenylethoxy)hexanamide mp 139"; Mass Spectrum: FAB 429 ((M+H) '+ ) ; nmr δ (dgDMSO) 1.20 (m, 2H) , 1.45 (m, 4H) , 2.00 (t, 2H) , 2.77 (t, 2H) , 3.23 (q, 2H) , 3.34 (m, 4H+H 2 0) , 3.55 (t, 2H) , 6.69 (d, IH) , 6.78 (d, IH) , 7.16-7.28 (m, 5H) , 7.84 (t, IH) ; Analysis: Found C,64.03; H,6.41; N,6.60; S,6.84% C 23 H 28 N 2°4 S r β C-iires: C,64.46; H,6.58; N,6.54; S,7.48%. ii. 4-Hvdroxy-7-r2-r6-.2-phenylethoxy)hexyl1aminoethyl]- 1.3-benzothiazol-2 (3H. -one hvdrochloride mp 219-222 β C (decomposes); Mass spectrum: FAB 415 ((M+H) + ); nmr δ (dgDMSO) 1.22-1.37 (m, 4H) , 1.47 (t, 2H) , 1.54-1.64 (m, 2H) , 2.8-2.9 (m, 6H) , 3.01-3.12 (brm, 2H) , 3.34-3.47 (m, 2H) , 3.55 (t, 2H) , 6.76 (d, IH) , 6.88 (d, IH) , 7.06-7.32 (m, 5H) , 8.87 (brs, 2H) , 10.15 (s, IH) , 11.78 (s, IH) ; Analysis: Found C,60.82; H,6.53; N,6.01; S,6.63; Cl,8.34% C 3 H 30 N 2 O 3 S.HCl requires: C,61.25; H,6.93; N,6.21; S,7.11; Cl,7.86%. b) 4-Hydroxy-7-r2-f5-.3-phenylpropoxylpentyl " |aminoethyl1- 1.3-benzothiazol-2.3H. -one hvdrochloride i. N-f2-f4-Hvdroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyl1-5 -f3-phenylpropoxy)pentanamide mp 141-142 • ; Mass Spectrum: FAB 429 ((M+H) + ); nmr δ (CDC1 3 ) 1.60 (m, 2H) , 1.70 (m, 2H) , 1.87 (m, 2H) , 2.18 (t, 2H) , 2.66 (t, 2H) , 2.74 (t, 2H) , 3.40 (m, 4H) , 3.49 (q, 2H) , 6.18 (t, IH) , 6.74 (d, IH) , 6.80 (d, IH) , 7.18 (m, 3H) , 7.27 (m, 2H) , 8.71 (brs, 4H) , 10.07 (s, IH) ; Analysis: Found C,64.14; H,6.57; N,6.77; S,7.45% C 23 H 2 8 N 2°4 S requires: C,64.46; H,6.58; N,6.54; S,7.48%. ii. 4-Hvdroxy-7- \ 2- \5-,3-phenylp opoxy)pentyl1aminoethyl1- 1.3-benzothiazol-2f3H.-one hydrochloride mp 211-212"; Mass Spectrum: FAB 415 ((M+H) + ); nmr δ (dgDMSO) 1.38 (m, 2H) , 1.51 (m, 2H) , 1.61 (m, 2H) , 1.79 (m, 2H) , 2.61 (t, 2H) , 2.86 (m, 4H) , 3.06 (brm, 2H) , 3.35 (m, 4H) , 6.76 (d, IH) , 6.86 (d, IH) , 7.17 (m, 3H) , 7.27 (m, 2H) , 8.81 (brs, 2H) , 10.13 (S, IH) , 11.77 (s, IH); Analysis: Found C,60.83; H,7.02; N,6.21; S,6.94; Cl,8.04% C 23 H 3 oN 2 0 3 S.HCl requires: C,61.25; H,6.93; N,6.21; S,7.11; Cl,7.88%. c) 4-Hvdroxy-7- 2-f5-T2-,5-methylfuranyl.1 entyl]- aminoethyll-1.3-benzothiazol-2(3H.-one trifluoroacetate i. N-.2-U-Hvdroxy-2-oxo-3H-1.3-benzothiazol-7-yl.ethyl1- 5- (5-methylfuran-2-yl.pentanamide mp 153-154"; nmr δ (dgDMSO) 1.47-1.51 (m, 4H) ,.2.03-2.04 (m, 2H) , 2.20 (S, 3H) , 2.5 (2H+DMSO) , 2.59 (t, 2H) , 3.23 (q, 2H) , 5.90-5.92 (m, 2H) , 6.69 (d, IH) , 6.78 (d, IH) , 7.87 (t, IH) , 9.89 (s, IH) , 11.61 (S, IH) ; Mass Spectrum: FAB 375 ((M+H) + ). ii. 4-Hvdroxy-7-r2-r5-r2- (5-methylfuranyl_ 1pentyl1- aminoethyll-1.3-benzothiazol-2.3H_-one trifluoroacetate mp 237-239" (decomposes); nmr δ (dgDMSO) 1.30-1.38 (m, 2H) , 1.53-1.64 (m, 4H) , 2.20 (S, 3H) , 2.54 (t, 2H) , 2.81 (brt, 2H) , 2.94 (t, 2H) , 3.10 (t, 2H) , 5.93 (m, 2H) , 6.75 (d, IH) , 6.86 (d, IH) , 8.56 (brs, 2H) , 10.17 (brs, IH) , 11.73 (brs, IH) ; Analysis: Found C,53.27; H,5.46; N,6.00; S,6.66% C 19 H 24 N 2°3 S ' CF 3 C0 2 H * H 2° requ res: C,53.04; H,5.51; N,5.89; S,6.80%. d) 4-Hydroxy-7-r2-[7-.2-phenylethoxy)heptyl]aminoethyl1- 1.3-benzothiazol-2(3H)-one hydrochloride i. N-f2-f4-Hydroxy-2-oxo-3H-1.3- ' benzothiazol-7-yl)ethyll- 7- (2-phenylethoxy)heptanamide mp 140-142° ; nmr δ (dgDMSO) 1.17-1.24 (m, 4H) , 1.43-1.48 (m, 4H ), 2.00 (t, 2H) , 2.58 (t, 2H) , 2.79 (t, 2H) , 3.23 (q, 2H) , 3.33-3.67 (m, 2H) , 3.54 (t, 2H) , 6.69 (d, IH) , 6.78 (d, IH) , 7.16-7.29 (m, 5H) , 7.48 (t, IH) , 9.89 (s, IH) , 11.61 (s, IH) ; ii. 4-Hydroxy-7-r2-f7-.2-phenylethoxy.heptyl1aminoethyl]- 1.3-benzothiazol-2 (3H)-one hydrochloride mp 225-227" ; nmr δ (dgDMSO) 1.26 (brs, 6H) , 1.43-1.52 (m, 2H) , 1.54-1.64 (m, 2H) , 2.79 (t, 2H) , 2.86-2.92 (m, 4H) , 3.01-3.11 (m, 2H) , 3.67 (t, 2H+H 2 0) , 3.56 (t, 2H) , 6.78 (d, IH) , 6.87 (d, IH) , 7.16-7.30 ( , 5H) , 8.98 (brs, 2H) , 10.16 (s, IH) , 11.79 (s, IH) ; Analysis: Found C,61.70; H,7.12; N,6.20; S,6.92% C 24 H 3 N 2 0 3 S.HC1 requires: C,61.98; H,7.15; N,6.02; S,6.89%. e) 4-Hydroxy-7-[2-[4-.2-phenylethoxy)butyl]aminoethyl]- 1.3-benzothiazol-2 (3H. -one hydrochloride i. N-f2-.4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl1- 4-(2-phenylethoxy)butanamide Mass Spectrum: FAB 401 ((M+H) + ); nmr 5 (CDCl 3 +dgDMSO) 1.67-1.81 (m, 2H) , 2.09 (t, 2H) , 2.61 (t, 2H) , 2.77 (t, 2H) , 3.30-3.36 (m, 4H) , 3.53 (t, 2H) , 6.40 (brs, IH) , 6.66 (d, IH) , 6.71 (d, IH) , 7.12-7.20 (m, 5H) , 8.88 (brs, IH) , 10.49 (brs, IH) . ii. 4-Hydroxy-7-r2-r4- ( 2-phenylethoxy)butyl1aminoethyl]- 1.3-benzothiazol-2.3H)-one hydrochloride mp 204-205" ; nmr δ (dgDMSO) 1.52-1.57 (m, 2H) , 1.61-1.69 (m, 2H) , 2.80 (t, 2H) , 2.84-2.89 (m, 4H) , 3.02 (brm, 2H) , 3.40 (t, 2H) , 3.57 (t, 2H) , 6.78 (d, IH) , 6.87 (d, IH) , 7.15-7.29 (m, 5H) , 8.96 (brs, 2H) , 10.18 (s, IH) , 11.80 (s, IH) ; Analysis: Found C,59.40; H,6.51; N,6.56; S,7.77; Cl,8.00% C 21 H 2 6 N 2° 3 S,HC ^ requires: C,59.64; H,6.20; N,6.62; S,7.58; Cl,8.30%. f) 4-Hydroxy-7-r2- 5-,2-phenylethoxy) entyl1aminoethyll- 1.3-benzothiazol-2 (3H)-one hydrochloride i. N-.2- -Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyl1- 5-.2-phenylethoxy)pentanamide Mass Spectrum: FAB 415 ((M+H) + ) nmr δ (CDC1 3 ) 1.50-1.60 (m, 2H) , 1.60-1.70 (m, 2H) , 2.18 (brt, 2H) , 2.67 (m, 2H) , 2.86 (t, 2H) , 3.44 (t, 2H) 3.45-3.53 (m, 2H) , 3.66 (t, 2H) , 6.3 (brs, IH) , 6.65 (d, IH) , 6.72 (d, IH) , 7.19-7.26 (m, 6H) , 9.60 (s, IH) . ii * 4-Hydroxy-7-r2-r5-.2-phenylethoxy) entyl1aminoethyl1- 1.3-benzothiazol-2.3H)-one hydrochloride mp 209-210"; nmr δ (dgDMSO) 1.28-1.35 (m, 2H) , 1.48-1.52 (m, 2H) , 1.57-1.68 (m, 2H) , 2.80 (t, 2H) , 2.85-2.94 (m, 4H) , 3.05 (brs, 2H) , 3.38 (t, 2H+H 2 0) , 3.56 (t, 2H) , 6.78 (d, IH) , 6.87 (d, IH) , 7.19-7.30 (m, 5H) , 8.93 (brs, 2H) , 10.16 (S, IH) , 11.79 (S, IH) ; Analysis: Found C,60.09; H,6.45; N,6.36; Cl,9.30% C 22 H 28 N 0 3 S.HC1 requires: C,60.47; H,6.69; N,6.41; Cl,8.11%. g) 4-Hydroxy-7-r2-[6-. henylroethoxy)hexyl]aminoethyl1- 1.3-benzothiazol-2(3H)-one hydrochloride i. N-r2-f4-Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyiy 6-(phenylmethoxy)hexanamide Mass Spectrum: FAB 429 ((M+H) + ); mp 133-134° ; nmr δ (dgDMSO) 1.2-1.3 (m, 2H) , 1.4-1.55 (m, 4H) , 2.01 (t, 2H) , 2.57 (t, 2H) , 3.2-3.3 (m, 2H) , 3.3-3.4 (m, 2H) , 4.44 (S, 2H) , 6.69 (d, IH) , 6.78 (d, IH) , 7.24-7.37 (m, 5H) , 7.85 (t, IH) , 9.91 (s, IH) , 11.61 (s, IH) . ii. 4-Hydroxy-7-r2-r6-.phenylmeth ' oxy)hexyl1aminoethyl]- 1.3-benzothiazol-2.3H)-one hydrochloride mp 208-211" ; nmr <S (dgDMSO) 1.27-1.38 (1, 4H) , 1.5-1.65 (m, 4H) , 2.81-2.94 (m, 4H) , 3.02-3.11 (m, 2H) , 3.42 (t, 2H) , 4.45 (S, 2H) , 6.76 (d, IH) , 6.86 (d, IH) , 7.25-7.38 (m, 5H) , 8.81 (brs, 2H) , 10.13 (s, IH) , 11.77 (s, IH) ; Analysis: Found C,59.42; H,6.85; N,6.37; S,7.25; Cl,9.44% C H 8 N 2 0 3 S.HC1 requires for 0.17 moles excess HC1: C,59.55; H,6.63; N,6.31; S,7.23; Cl,9.45%. h) 4-Hvdroxy-7-r2-f4-.4-phenylbutoxy)butyl1aminoethyl1- 1.3-benzothiazol-2.3H)-one hydrochloride i. N-f2-f4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl- 4-.4-phenylbutoxy)butanamide mp 133-135"; Mass Spectrum: FAB 429 ((M+H) + ); nmr δ (CDC1 3 ) 1.06-1.23 (m, 4H) , 1.36 (q, 2H) , 1.73 (t, 2H) , 2.11-2.17 (m, 4H) , 2.23 (t, 2H) , 2.91-2.94 (m, 4H) , 6.25 (d, IH) , 6.31 (d, IH) , 6.66-6.81 (m, 6H) , 8.67 (S, IH) , 10.42 (s, IH) . ii. 4-Hvdroxy-7- 2-f4-,4-phenylbutoxy)butyl]aminoethyl1- 1.3-benzothiazol-2 (3H)-one hydrochloride mp 208" ; nmr δ (dgDMSO) 1.6 (brm, 8H) , 2.58 (t, 2H) , 2.88 (brm, 4H) , 3.05 (t, 2H) , 3.45 (m, 4H+H 2 0) , 6.77 (d, IH) , 6 . 86 (d, IH) , 7 . 18 (m, 3H) , 7 .26 ( , 2H) , 8 . 91 (brs , 2H) , 10 . 16 (5 , IH) ; Analysis: Found C,59.21; H,7.08; N,6.17; S,7.22; Cl,8.16% C 23 H 30 N 2 O 3 S.HC1.0.97H 2 O requires: C,58.90; H,7.03; N,5.97; S,6.82; Cl,7.60%. i) 4-Hydroxy-7-.2-.6-phenoxyhexyl)aminoethyll-1.3- benzothiazol-2.3H)-one hydrochloride i. N-r2-U-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl1- 6-phenoxyhexanamide mp 161.5-162.5" ; Mass Spectrum: FAB 407 ((M+H) + ); nmr δ (dgDMSO) 1.30-1.39 (m, 2H) , 1.48-1.57 (q, 2H) , 1.64-1.72 (m, 2H) , 2.03-2.06 (t, 2H) , 2.57-2.61 (t, 2H) , 3.21-3.26 (m, 2H) , 3.90-3.94 (t, 2H) , 6.68-6.80 (m, 2H) , 6.88-6.91 (m, 3H) , 7.24-7.29 (t, 2H) , 7.85-7.89 (t, IH) . ii. 4-Hydroxy-7-r2-(6-phenoxyhexyl)aminoethyl]-1.3- benzothiazol-2 (3H)-one hydrochloride mp 213-214" ; nmr δ (dgDMSO) 1.26-1.50 (m, 4H) , 1.55-1.65 (quin, 2H) , 1.65-1.78 (quin, 2H) , 2.80-2.85 (t, 2H) , 2.90-2.94 (t, 2H) , 3.06-3.09 (t, 2H) , 3.94-3.97 (t, 2H) , 6.74+6.87 (2xd, 2H) , 6.90-6.93 (m, 3H) , 7.25-7.29 (t, 2H) , 8.59 (brs, 2H) , 10.10 (brs, 2H) ; Analysis: Found C,58.93; H,6.49; N,6.71; S,6.94% C 21 H 6 N 2 O 3 S.HC1.0.36H 2 O requires: C,58.74; H,6.50; N,6.52; S,7.47%. j) 4-Hydroxy-7- 2-f6- (3-phenylpropoxy)hexyl1aminoethyl1- 1.3-benzothiazol-2.3H)-one oxalate i. N-,2-.4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl]- 6- (3- henylpropoxy)hexanamide Mass Spectrum: FAB 443 ((M+H) + ). ii. 4-Hydroxy-7-f2-f6-.3-phenylpropoxy)hexyl]aminoethyl]- 1.3-benzothiazol-2 _3H)-one oxalate mp 238-240° (decomposes) ; nmr δ (dgDMSO) 1.31 (brs, 4H) , 1.42-1.67 (m, 4H) , 1.74-1.81 (quin, 2H) , 2.58-2.63 (t, 2H) , 2.79-2,85 (brt, 2H) , 2.89-2.93 (brt, 2H) , 3.05-3.10 (brt, 2H) , 3.92-3.55 (t, 4H) , 6.74-6.76 (d, IH) , 6.84-6.86 (d, IH) , 7.15-7.29 (m, 5H) , 8.4-9.2 (v.brs, not integrated); Analysis: Found C,59.30; H,6.49; N,5.17% C 24 32 N 2°3 S - 1 ' 6 C 2 H 2°4 requires: C,59.30; H,6.44; N,5.26%. k) 4-Hydroxy-7-r2-r2- (4-methoxyp ' henyl)ethyl1aminoethyl]- 1.3-benzothiazol-2.3H)-one hydrochloride i. N-|"2-(4-Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyl]- .4-methoxyphenyl)acetamide Mass spectrum: FAB 359 ((M+H) + ). ii. 4-Hvdroxy-7-r2-r2-.4-methoxypheny1)ethyl]aminoethy ]- 1.3-benzothiazol-2.3H)-one hydrochloride mp 275-280° ; Mass spectrum: FAB 345 ((M+H) + ); nmr δ (dgDMSO) 2.80-2.90 (m, 4H) , 3.10-3.20 (brm, 4H) , 3.73 (s, 3H) , 6.77 (d, IH) , 6.86 (d, IH) , 6.90 (d, 2H) , 7.18 (d, 2H) , 9.00 (brs, 2H) , 10.15 (s, IH) , 11.78 (s, IH) ; Analysis: Found C,56.52; H,5.48; N,7.23% C 18 H 20 N 2 0 3 S.HC1 requires: C,56.76; H,5.56; N,7.35%. 1) 4-Hydroxy-7-r2-r2.2-Dimethyl-6-.2-phenylethoxy)hexyl1- aminoethyl]—1.3-benzothiazol-2 (3H)-one hydrochloride i. N-r2-.4-hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl]- 2,2-dimethyl-6-.2-phenylethoxy)hexanamide mp 136-138°; Mass spectrum: FAB 457 ((M+H) + ); nmr δ (dgDMSO) 1.00 (s, 6H) , 1.08-1.12 (m, 2H) , 1.34-1.41 (m, 4H) , 2.60 (t, 2H) , 2.77 (t, 2H) , 3.25 (q, 2H) , 3.32 (t, 2H) , 3.53 (t, 2H) , 6.69 (d, IH) , 6.77 (d, IH) , 7.15-7.27 (m, 5H) , 7.49 (t, IH) , 9.88 (brs, IH) , 11.61 (brs , IH) ; Analysis: Found C,65.84; H,7.31; N,6.49; S,6.81% C 25 H 32 N 2 0 4 S requires: C,65.76; H,7.06; N,6.16; S,7.02%. ii. 4-Hydroxy-7-r2-r2.2-Dimethyl-6- ( 2-phenylethoxy)hexyl]- aminoethyl]-1.3-benzothiazol-2 (3H)-one hydrochloride mp 224-225° ; Mass Spectrum: FAB 443 ((M+H) + ); nmr δ (dgDMSO) 0.96 (s, 6H) , 1.21-1.30 (m, 4H) , 0 1.45-1.48 (m, 2H) , 2.78-2.82 (m, 4H) , 2.95-2.99 (m, 2H) , 3.02-3.12 (m, 2H) , 3.39 (t, 2H) , 3.57 (t, 2H) , 6.78 (d, IH) , 6.87 (d, IH) , 7.16-7.29 (m, 5H) , 8.58 (brs, 2H) , 10.17 (S, IH) , 11.78 (S, IH) ; Analysis: Found C,62.62; H,7.51; N,5.91; S,6.67; l - Cl,8.11% C 25 H 34 N 2 0 3 S.HC1 requires: C,62.27; H,7.36; N,5.85; S,6.69; Cl,7.40%. ) 4-Hydroxy-7-r2-r6-.2-phenylethylsulphonyl)hexyl1amino¬ ethyl]-1.3-benzothiazol-2.3H)-one hydrochloride 20 i. N-f2-.4-Hydroxy-2-oxo-l.3-benzothiazol-7-yl)ethyl1-6- .2-phenylethylsulphonyl)hexanamide mp 174-188"; Mass Spectrum: FAB 477 ((M+H) + ); nmr δ (dgDMSO) 1.27-1.33 (m, 2H) , 1.44-1.52 (m, 25 2H) , 1.61-1.70 (m, 2H) , 2.01-2.05 (t, 2H) , 2.57-2.61 (t, 2H) , 2.98-3.07 (m, 4H) , 3.20-3.26 (m, 2H) , 3.37-3.43 (m, 2H) , 6.69-6.86 (dd, 2H) , 7.21-7.31 (m, 5H) , 7.86-7.89 (t, IH) , 9.91 (s, IH) , 11.62 (s, IH) . ii. 4-Hydroxy-7-r2-r6-.2-phenylethylsulphonyl)hexyl]amino- 30 ethyl1-1.3-benzothiazol-2.3H)-one hydrochloride mp 210-211"; Mass Spectrum: FAB 463 ((M+H) + ); nmr δ (dgDMSO) 1.35 (brs, 4H) , 1.60 (brm, 2H) , 1.68 (brm, 2H) , 2.83-2.91 (m, 4H) , 2.98-3.10 ( , 6H) , 35 3.37-3.42 (m, 2H) , 6.75-6.88 (dd, 2H) , 7.23-7.26 (m, IH) , 7.31-7.32 (m, 4H) , 8.7 (v.brs, 2H) ; Analysis: Found C,52.93; H,6.15; N,5.59; S,12.15% C 23 H 30 N 2 O 4 S.HCl.H 2 O requires: C,53.40; H,6.43; N,5.41; S,12.39%. n) N-[6-r2-f4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl) - ethylamino] hexyl ]-N'-phenyl urea hvdrochloride i. N-r2-f4-Hydroxy-2-oxo-1.3-benzothiazol-7-yl)ethvπ-6- (phenylaminocarbonylamino)hexanamide mp 186-188" ; Mass Spectrum: 443 ((M+H) + ); nmr δ (dgDMSO) 1.23-1.27 (m, 2H) , 1.36-1.52 (m, 4H) , 2.01-2.05 (t, 2H) , 2.56-2.60 (t, 2H) , 2.60-3.05 (q, 2H) , 3.23 (q, 2H) , 6.09 (t, 2H) , 6.68-6.79 (dd, 2H) , 6.87 (t, IH) , 7.19 (t, 2H) , 7.35-7.37 (d, 2H) , 7.86 (t, 2H) , 8.37 (s, IH) . ii. N-f6-r2-_4-Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl)- ethylamino]hexyl.-N'-phenyl urea hydrochloride mp 209-210" ; Mass Spectrum: FAB 429 ((M+H) + ); nmr δ (dgDMSO) 1.25-1.65 (m, 8H) , 2.75-3.15 (m, 8H) , 6.18-6.21 (t, IH) , 6.73-6.76 (d, IH) , 6.85-6.89 (t, 2H) , 7.18-7.22 (t, 2H) , 7.36-7.38 (d, 2H) , 8.45 (brs, 3H) , 10.13 (s, IH) , 11.75 (s, IH) ; Analysis: Found C,52.55; H,5.35; N,10.24; S,5.15% C 21 H 9 N 4 0 3 S.HC1.0.64 CF 3 C0 2 H requires: C,51.99; H,5.55; N,10.41; S,5.96%. o) 4-Hydroxy-7-f2-f6-[2-.4-nitrophenyl)ethoxy]hexyl]amino¬ ethyl]-1.3-benzothiazol-2(3H)-one hydrochloride Prepared by the method of Example lb) using the amide of Example 11a) . mp 160-163"; Mass spectrum: FAB 460 ((M+H) + ); nmr δ (dgDMSO) 1.27 (m, 4H) , 1.45 (m, 2H) , 1.58 (m, 2H) , 2.86 (m, 4H) , 2.95 (t, 2H) , 3.05 (brm, 2H) , 3.38-3.62 (t, 2X2H) , 6.76-6.86 (dd, 2H) , 7.53-8.15 (dd. 4H) , 8 . 88 ( 2H) , 10. 14 (s , IH) , 11. 77 (s , IH) ; Analysis: Found C,55.35; H,6.08; N,8.48; S,6.62; Cl,7.8% C 23 H 2g N 3 0 5 S.HCl requires: C,55.69; H,6.09; N,8.47; S,6.42; Cl,7.15%. p) 4-Hydroxy-7-.2-r6-f2-(4-hydroxyphenyl)ethoxy1-2.2- dimethylhexyl]aminoethyl]-1.3-benzothiazol-2 (3H)-one hvdrochloride i. 6-.2-f4-Hvdroxyphenyl) thoxyl-N-.2- (4-hvdroxy-2-oxo-3H- 1.3-benzothiazol-7-yl)ethyl1-2.2-dimethylhexanamide Mass Spectrum: FAB 473 ((M+H) + ); nmr δ (d 4 MeOH) 0.98 (s)+1.00-1.05 (m) (8H) , 1.29-1.37 (m, 4H) , 2.60-2.65 (m, 4H) , 3.25-3.47 (m, 6H+H 2 0) , 6.55-6.60 (m, 3H) , 6.73-6.75 (d, IH) , 6.89-6.92 (dd, 2H) . ii. 4-Hvdroxy-7-f2-r6-r2-f4-hydroxyphenyl)ethoxy1-2.2- di ethylhexyl]aminoethyl]-1.3-benzothiazol-2 (3H)-one hvdrochloride mp 204-205" ; Mass Spectrum: FAB 459 ((M+H) + ); nmr δ (dgDMSO) 0.95 (s, 6H) , 1.25 (brs, 4H) , 1.45-1.48 (brt, 2H) , 2.65-2.69 (t, 2H) , 2.81 (brs, 2H) , 2.90-2.95 (brm, 2H) , 3.07 (brs, 2H) , 3.37 (m, 2H+H 2 0) , 3.47-3.51 (t, 2H) , 6.64-6.67 (d, 2H) , 6.75-6.77 (d, IH) , 6.85-6.87 (d, IH) , 6.99-7.01 (d, 2H) , 8.35 (brs, 2H) , 9.2 (s, IH) , 10.1 (s, IH) , 11.8 (s, IH) ; Analysis: Found C,58.07; H,7.29; N,5.42; S,6.19% C 25 H 34 N 2 0 4 S.HC1 (1.22M H 2 0) requires: C,58.07; H,7.41; N,5.46; S,5.84%. q) 7-Hvdroxy-4-r2-T6-f2-.1-naphthyl)ethoxylhexyl1amino- ethyll-1.3-benzothiazol-2 (3H)-one hvdrochloride i. N-r2-(4-Hvdroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyll- 6- 2- (1-naphthyl)ethoxy1hexanamide Mass Spectrum: FAB 479 ((M+H) + ). ii. 7-Hvdroxy-4- 2-r6- 2- (1-naphthyl)ethoxylhexyl]amino- ethyl]-1.3-benzothiazol-2(3H)-one hydrochloride mp 194-196° ; Mass Spectrum: FAB 465 ((M+H) + ); nmr δ (dgDMSO) 1.27 (brs, 4H) , 1.47 (brs, 2H) , 1.57 (brs, 2H) , 2.86 (brd, 4H) , 3.04 (brs, 2H) , 3.28 (t, 2H) , 3.40 (t, 2H) , 3.68 (t, 2H) , 6.76 (d, IH) , 6.86 (d, IH) , 7.43 (m, 2H) , 7.52 (m, 2H) , 7.78 (d, IH) , 7.91 (d, IH) , 8.68 (d, IH) , 9.8 (brs, 2H) , 10.13 (s, IH) , 11.77 (s, IH) ; Analysis: Found C,64.47; H,6.69; N,5.71; S,6.19% C 27 H 32 N 2 0 3 S.HC1 requires: C,64.71; H,6.64; N,5.59; S,6.40%. r) 7-r2-[6-(2-Cyclohexylethox )hexyl]aminoethyl]-4-hydroxy -1.3-benzothiazol-2f3H)-one hydrochloride i. 6- (2-Cyclohexylethoxy)-N-r2-('4-hvdroxy-2-oxo-3H-l.3- benzothiazol-7-yl)ethyl]hexanamide Mass Spectrum: FAB 435 ((M+H) + ); nmr «5 (CDCl 3 +d 6 DMSO) 0.85 (m, 2H) , 1.0-1.7 (m, 17H) , 2.1 (t, 2H) , 2.6 (t, 2H) , 3.3 (m, 6H) , 6.7 (d, IH) , 6.5 (d, IH) , 6.9 (t, IH) , 10.7 (brs, IH) ; ii. 7- [ 2-[6- (2-Cvclohexylethoxy)hexyl1aminoethyl]-4-hvdroxy -1.3-benzothiazol-2(3H)-one hydrochloride mp 224-227°; Mass Spectrum: FAB 421 ((M+H) + nmr δ (dgDMSO) 0.88 ( , 2H) , 1.0-1.25 (m, 3H) , 1.25-1.40 (m, 7H) , 1.40-1.55 (m, 2H) , 1.55-1.7 (m, 7H) , 2.83 (m, 2H) , 2.90 (m, 2H) , 3.05 (m, 2H) , 3.0-3.4 (m, 4H+H 2 0) , 6.75 (d, IH) , 6.86 (d, IH) , 8.7 (brs, 2H) , 10.11 (s, IH) , 11.76 (brs, IH) ; Analysis: Found C,59.88; H,8.08; N,6.19; S,6.18; Cl,8.69% C 23 H 36 N 2 0 3 S.HC1 requires: C,59.88; H,8.11; N,6.07; S,6.95; Cl,8.57%. s) 7-r2-r6-T2- (4-Bromophenyl)ethoxy]hexyl]aminoethyl]-4- hydroxy-1.3-benzothiazol-2 (3H)-one hydrochloride i. 6-r2-f4-Bromophenyl)ethoxy]-N-r2-(4-hydroxy-2-oxo-3H- 1,3-benzothiazol-7-yl)ethyl1hexanamide mp 143-145°; Mass Spectrum: FAB 507/9 ((M+H) + ); nmr δ (dgDMSO) 1.15-1.24 (m, 2H) , 1.42-1.49 (m, 4H) , 2.01 (t, 2H) , 2.59 (t, 2H) , 2.76 (t, 2H) , 3.18-3.30 (m, 2H) , 3.33 (t, 2H) , 3.53 (t, 2H) , 6.70 (d, IH) , 6.79 (d, IH) , 7.19 (d, 2H) , 7.45 (d, 2H) , 7.85 (t, IH) , 9.5-11.5 (v.brs, 2H) ; Analysis: Found C,54.39; H,5. ' 30; N,5.63; S,5.14; Br,16.96% C 23 H 27 N 0 4 SBr requires: C,54.44; H,5.36; N,5.52; S,6.32; Br,15.74%. ii. 7- 2-f6-f2-.4-Bromophenyl)ethoxy]hexy11aminoethyll-4- hvdroxy-1.3-benzothiazol-2 (3H)-one hvdrochloride mp 199-200° ; Mass Spectrum: FAB 577/9 ((M+Rb) + ); nmr δ (dgDMSO) 1.22-1.37 (m, 4H) , 1.42-1.51 (m, 2H) , 1.57-1.64 (m, 2H) , 2.77 (t, 2H) , 2.85-2.96 (m, 4H) , 3.06 (t, 2H) , 3.36 (t, 2H+H 2 0) , 3.55 (t, 2H) , 6.78 (d, IH) , 6.87 (d, IH) , 7.20 (d, 2H) , 7.46 (d, 2H) , 9.1 (v.brs, IH) , 10.2 (v.brs, IH) ; Analysis: Found C,51.98; H,5.68; N,5.39; S,5.94; Cl,7.02% C 23 H 29 N 2 0 3 SBr.HCl requires: C,52.13; H,5.71; N,5.29; S,6.05; Cl,6.69%. t) 4-Hydroxy-7-f2-r6-r2- (2-thienyl)ethoxy]hexyl1amino¬ ethyl]-l.3-benzothiazol-2.3H)-one hvdrochloride i. N-r2-.4-Hydroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl1- 6-T2- ( 2-thienyl)ethoxy]hexanamide mp 130-132°; Mass Spectrum: FAB 435 ((M+H) + ); nmr δ (dgDMSO) 1.16-1.29 (m, 2H) , 1.40-1.57 (m, 4H) , 2.01 (t, 2H) , 2.59 (t, 2H) , 3.00 (2H, t) , 3.20-3.37 (m, 2H), 3.35-3.45 (m, 2H+H 2 0) , 3.56 (t, 2H) , 6.70 (d, IH) , 6. 79 (d , IH) , 6. 89 (brs , IH) , 6 . 92-6. 94 (m, IH) , 7 . 70 (d , IH) , 7 . 83-7 . 91 (m, IH) , 9 . 96 (brs , IH) , 11. 58 (brs , IH) ; Analysis: Found C,57.76; H,6.06; N,6.64; S,14.48% C 21 H 26 N 2°4 S 2 requires: C,58.04; H,6.03; N,6.45; S,14.48%. ii. 4-Hydroxy-7-[2- \6-f2- ( 2-thienyl)ethoxy1hexyl]amino¬ ethyl]-1.3-benzothiazol-2 (3H)-one hydrochloride mp 216-218°; Mass Spectrum: FAB 421 ((M+H) + ); nmr δ (dgDMSO) 1.31 (brs, 4H) , 1.47-1.53 (m, 2H) , 1.54-1.66 (m, 2H) , 2.84-2.93 (m, 4H) , 2.87 (t, 2H) , 2.89 (brs, 2H) , 3.40 (t, 2H) , 3.57 (t, 2H) , 6.77 (d, IH) , 6.87 (d, IH) , 6.89 (brs, IH) , 6.92-6.95 ( , IH) , 7.31 (dd, IH) , 9.01 (brs, 2H) , 10.16 (s, IH) , 11.78 (s, IH) ; Analysis: Found C,55.40; H,6.47; N,6.28; S,13.86; Cl,7.38% 21 H 28 N 2°3 S 2* HC1 requires: C,55.11; H,6.39; N,6.13; S,14.02; Cl,7.76%. u) CR.S)-4-Hydroxy-7-[2-f2-methyl-6- (2-phenylethoxy)hexyl] -aminoethyl]-!.3-benzothiazol-2 (3H)-one hydrochloride i. N-r2-(4-Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyl1- 2-methyl-6-.2-phenylethoxy)hexanamide Mass Spectrum: 443 ((M+H) + ). ii. (R.S)-4-Hydroxy-7-[2-r2-methyl-6-f2-phenylethoxy)hexyl] -aminoethyl]-!.3-benzothiazol-2.3H)-one hydrochloride mp 211-212°; Mass Spectrum: FAB 429 ((M+H) + ); nmr δ (dgDMSO) 0.94 (d, 3H) , 1.11-1.51 (m, 6H) , 1.80-1.85 (m, IH) , 2.70-2.93 (m, 6H) , 3.01-3.11 (m, 2H) , 3.38 (t, 2H) , 3.56 (t, 2H) , 6.78 (d, IH) , 6.86 (d, IH) , 7.16-7.29 (m, 5H) , 8.82 (brs, 2H) , 10.15 (s, IH) , 11.78 (s, IH) ; Analysis: Found C,61.31; H,7.31; N,6.11; S,6.78% C 24 H 32 N 2 0 3 S.HC1 requires: C,61.98; H,7.15; N , 6. 02 ; S , 6. 98% . v) 1.3-Dihydro-4-hvdroxy-7-r2-r6- ( 2-phenylethoxy)hexyl]- aminoethyll-2H-benzimidazol-2-one hydrochloride i. N- \2- (1.3-Dihvdro-4-hvdroxy-2-oxo-2H-l.3-benzimidazol- 7-yl)ethyl]-6-.2-phenylethoxy)hexanamide Prepared by the method of Example la) from 7-(2-aminoethyl)-4-hydroxy-benzimidazol-2(3H)-one hydrobromide, which was prepared from N-[2-(3-amino-4- ethoxyphenyl)ethyl]trifluoroacetamide using a procedure outlined in J. Med. Chem.. 1987, 30., 1166. mp 205-207"; Mass Spectrum: FAB 412 ((M+H) + ); nmr δ (dgDMSO) 1.18-1.24 (m, 2H) , 1.43-1.49 (m, 4H) , 2.01 (t, 2H) , 2.65 (t, 2H) , 2.79 (t, 2H) , 3.21 (q, 2H) , 3.34 (m, 2H+H 2 0) , 3.55 (t, 2H) , 6.36 (d, IH) , 6.53 (d, IH) , 7.16-7.29 (m, 5H) , 7.30 (t, IH) , 9.30 (s, IH) , 10.32 (S, IH) , 10.53 (s, IH) ; Analysis: Found C,64.34; H,7.14; N,9.92% C 2 3 H 29 N 3°4* 0 * 88 H 2° requires: C,64.65 ; H,7.25; N,9.83%. ii. 1.3-Dihydro-4-hvdroxy-7-r2-r6- (2-phenylethoxy)hexyl]- aminoethyl]-2H-benzimidazol-2-one hydrochloride mp 222-224° ; Mass Spectrum: FAB 398 ((M+H) + ); nmr δ (dgDMSO) 1.22-1.33 (m, 4H) , 1.43-1.51 (m, 2H) , 1.53-1.65 (m, 2H) , 2.79 (t, 2H) , 2.81-2.92 (m, 4H) , 3.01-3.09 (m, 2H) , 3.38 (m, 2H+H 2 0) , 3.56 (t, 2H) , 6.41 (d, IH) , 6.62 (d, IH) , 7.16-7.30 (m, 5H) , 8.73 (brs, 2H) , 9.54 (S, IH), 10.48 (s, IH) , 10.65 (s, IH) ; Analysis: found C,63.30; H,7.52; N,6.67; Cl,8.11% C 23 H 31 N 3 0 3 .HC1 requires: C,63.65; H,7.43; N,6.68; Cl,8.17%. Example 3 4-Hydroxy-7-_2-r6-r2-f4-hydroxyphen 1)ethoxy]hexyl1- aminoethyll-1.3-benzothiazol-2 (3H)-one trifluoroacetate a) N-r2-(4-Hydroxy-2-oxo-3H-1.3-benzothiazol-7-yl) ethyl] 6-r2- ,4-phenylmethoxy) henylethoxγ]hexanamide The sub-titled amide was prepared according to the method of Example la) . mp 148-150° ; Mass Spectrum: FAB 535 (M++H) + ); nmr δ (dgDMSO) 1.25-1.67 (m, 2H) , 1.41-1.50 (m, 4H) , 2.01 (t, 2H) , 2.59 (t, 2H) , 2.72 (t, 2H) , 3.24 (q, 2H) , 3.33 (t, 2H) , 3.49 (t, 2H) , 5.05 (s, 2H) , 6.69-6.80 (2xd, 2H) , 6.89-7.14 (dd, 4H) , 7.30-7.44 (m, 5H) , 9.92 (s, IH) , 11.63 (s, IH) . b) 4-Hydroxy-7-r2—rβ—r2- (4-phenylmethoxy)phenylethoxy]- hexylamino]ethyl]-l,3-benzothiazol-2.3H)-one hvdrochloride The sub-titled compound was prepared according to the method of Example lb) , from the intermediate amide of step a) . mp 228-230° ; nmr δ (dgDMSO) 1.29 (brs, 4H) , 1.41-1.49 (m, 2H) , 1.61 (brs, 2H) , 2.70-2.74 (t, 2H) , 2.85-2.90 (m, 4H) , 3.05 (brs, 2H) , 3.34-3.38 (t, 2H) , 3.48-3.52 (t, 2H) , 5.06 (s, 2H) , 6.77-6.88 (2xd, 2H) , 6.90-6.93+7.13-7.15 (dd, 4H) , 7.30-7.43 (m, 5H) , 8.9-9.0 (brs, 2H) , 10.18 (brs, IH) , 11.80 (s, IH) ; Analysis: Found C,64.84; H,6.80; N,5.17; S,5.55% C 30 H 3 gN 2 O 4 S.HCl requires: C,64.69; H,6.64; N,5.03; S,5.75%. c) 4-Hydroxy-7- \2- \6-f2-(4-hydroxyphenyl)ethoxy]hexyl]- aminoethyl]-!.3-benzothiazol-2.3H)-one trifluoroacetate A solution of the benzyl ether from step b) (0.79 g) in methanol (50 ml) was treated with cone, hydrochloric acid to pH 1 and hydrogenated over 10% palladium on carbon (0.50 g) for 8 days, the catalyst being replaced with a fresh portion after 7 days. The mixture was diluted with methanol (100 ml) boiled for 10 min and hot filtered. The filtrate was evaporated to give a yellow semi-solid. HPLC using methanol:0.1% TFA in water (50:50) as eluant, gave the title salt as a white powder. mp 192-197° ; nmr δ (dgDMSO) 1.29 (brs, 4H) , 1.48-1.56 (brm, 4H) , 2.65-2.67 (t, 2H) , 2.80-2.82 (t, 2H) , 2.90+3.08 (brs, 4H) , 3.36-3.38 (t, 2H+H 2 0) ■ 3.46-3.50 (t, 2H) , 6.66+7.00 (dd, 4H) , 6.75+6.86 (2xd, 2H) ; Analysis: Found C,55.01; H,5.85; N,5.12; S,5.29% C 3 H 30 N 2 O 4 S.CF 3 CO 2 H requires: C,55.24; H,5.56; N,5.15; S,5.90%. Example 4 2.3-Dihvdro-7-hvdroxy-4-r2-f6--Phenylethoxy)hexyll- aminoethyl1-indol-2-one hydrochloride a) N- 2- (3-Nitro-4-phenylmethoxy) henyl]ethyl-N-phenyl- methyl-6- ( 2-phenylethox )hexanamide A solution of N,0-bis-(phenylmethyl)-2-(4-hydroxy-3- nitrophenyl)ethylamine (7.5 g) , 6-[2-phenylethyoxy]- hexanoic acid (5.38 g) and carbonyldiimidazole (3.69 g) in dichloromethane (120 ml) was stirred at room temperature for 20 hours. Aqueous 5% hydrochloric acid (50 ml) was added and the mixture filtered, the organic layer was separated, washed with brine, (NaHC0 3 ) , and again with brine. After drying (MgS0 4 ) the solvent was removed under reduced pressure and the residue purified by chromatography (Si0 ) using ether/60-80° petroleum ether as eluant, to give the sub-titled compound as a yellow oil. Mass Spectrum: FAB 581 ((M+H) + ). b) N-f2- (3-Amino-4-phenylmethoxy)phenyl]ethyl-N-phenyl- methyl-6-(2-phenylethoxy)hexanamide The amide from step a) (7.0 g) was added to a suspension of iron powder (7.0 g) and ammonium chloride (7.0 g) in aqueous ethanol (90 ml ethanol:70 ml water). The suspension was stirred and heated to reflux for 2 hours. The hot reaction mixture was filtered (Hyflo Supergel) and the filtrate evaporated under reduced pressure. The residue was partitioned between dichloromethane and water, the organic layer was separated, dried (MgS0 4 ) and evaporated under reduced pressure to give the sub-titled compound as a yellow gum which was used without further purification. Mass Spectrum: FAB 551 ((M+H) + ); nmr δ (CDC1 3 ) 1.35 (m, 2H) , 1.57-1.65 (m, 4H) , 2.28 (m, 2H) , 2.65-2.73 (m, 2H) , 2.88 (m, 2H) , 3.40 (m, 2H) , 3.51 (t, 2H) , 3.61 (m, 2H) , 3.91 (brs, 2H) , 4.35 (s, IH) , 4.59 (s, IH) , 5.04 (s, 2H) , 6.42-6.57 (m, 2H) , 6.75 (d, IH) , 7.10 (d, IH) , 7.21-7.41 (m, 14H) . c) 3-Amino-N-r6-(2-phenylethoxy)hexyl .-4-phenylmethoxy-N- phenylmethyl 2-benzeneethanamide Borane (1M in THF, 20 ml) was added to a stirred solution of the compound from step b) (6.27 g) in tetrahydrofuran. The solution was heated under reflux for 18 hours, cooled and methanol (5 ml) added. The solvent was removed under reduced pressure and the residue dissolved in methanol. Ethanolic HC1 was added and the solution heated under reflux for 40 min, the solvent removed under reduced pressure, and the compound converted to the free base which was used in the next step without further purification. Mass Spectrum: FAB 537 ((M+H) + ). d) 1.3-Dihydro-3-methylthio-4-f2-[N-r6- ( 2-phenylethoxy)- hexyl]-N-(phenylmethyl)amino]ethyl]-7-phenylmethoxy)-2H- indol-2-one Sulfuryl chloride (0.81 ml) in dichloromethane was added dropwise to a solution of ethyl methylthioacetate in dichloromethane (25 ml) at -74°. The solution was stirred for 45 min and a solution of the compound from step c) (4.35 g) and Proton Sponge™ (1.74 g) in dry dichloromethane (50 ml) added dropwise. The mixture was stirred at -74° for 4 hours then triethylamine (1.17 ml) added. The mixture was allowed to warm to room temperature and stirred overnight. Aqueous 5% hydrochloric acid (35 ml) was added and stirring continued for 1 hour. The organic layer was separated, dried (MgS0 4 ) and the solvent removed under reduced pressure. Chromatography (Si0 2 ) using methanol/dichloromethane as eluant gave the sub-titled compound as a green oil. Mass Spectrum: FAB 623 ((M+H) + ). e) 1 f 3-Dihydro-4-r2-TN-f6-.2-phenylethoxy)hexyl1-N-.phenyl - ethyl)amino1ethyl .-7-phenylmethoxy-2Hindol-2-one Raney nickel (1.5 g) was added to a solution of the compound from step d) (2.1 g) in dry ethanol (60 ml). The mixture was heated to reflux for 1 hour, the catalyst was removed by filtration and the filtrate evaporated under reduced pressure. Trituration with ether gave an off-white solid which was purified by reverse phase HPLC (Si0 2 ) using methanol:chloroform as eluant. Recrystallisation from isopropyl alcohol gave the sub-titled compound as a buff coloured solid. mp 183-185" ; Mass Spectrum: FAB 577 ((M+H) + ); nmr δ (CDC1 3 ) 1.34 (m, 4H) , 1.55 (m, 2H) , 1.90 (m, 2H) , 2. SI (t, 2H) , 2.8-3.2 (m, 6H) , 3.3-3.5 (q, 4H) , 3.61 (t, 2H) , 4.22 (d, 2H) , 5.07 (s, 2H) , 6.77 (q, IH) , 7.20 (q, 3H) , 7.29 (m, 3H) , 7.38 (m, 5H) , 7.47 (t, 3H) , 7.61 (s, IH) , 7.66 (q, 2H) . Mass Spectrum: FAB 577 ((M+H) + ); f) 1.3-Dihvdro-7-hydroxy-4-r2-r6-(phenylethoxy)hexyl1- aminoethyl]-2H-indol-2-one hydrochloride The compound from step e) (0.18 g) was dissolved in dry ethanol (50 ml) containing 2 drops of cone, hydrochloric acid (sg. 1.18). The mixture was hydrogenated at atmospheric pressure using 5% Pd/C (0.020 g) as catalyst. After 4 hours the catalyst was removed by filtration and the solvent evaporated Under reduced pressure, recrystallisation from ethanol gave the title compound as a white solid. mp 277-278° (decomposes) ; Mass Spectrum: Thermal Spray Plasma 397 ((M+H) + ); nmr <S (dgDMSO) 1.28 (m, 4H) , 1.49 (t, 2H) , 1.59 (t, 2H) , 2.72-2.82 (m, 4H) , 2.88 (t, 2H) , 3.02 (t, 2H) , 3.36 (2H+H 2 0), 3.48 (s, 2H) , 3.56 (t, 2H) , 6.66 (q, 2H) , 7.21-7.28 (m, 5H) , 8.75 (brs, 2H) , 9.45 (s, IH) , 10.22 (s, IH) ; Analysis: Found C,65.96; H,7.67; N,6.58% C 23 H 32 N 2 0 3 .HC1 requires: C,66.51; H,7.68; N,6.47%. Example 5 4-Hydroxy-7-r2-r3-r2-(2-phenylethyl)aminoethyl]- sulphonylpropy11aminoethyl]-!.3-benzothiazol-2(3H)-one dihvdrochloride a) 3-r2-Oxo-2-(2-phenylethy1)amino1eth Ithiopropanoic acid A solution of 3-mercaptopropanoic acid (1.63 ml) in dimethylformamide (5 ml) was added gradually to a stirred suspension of sodium hydride (2 eq.) in dimethylformamide at room temperature. The suspension was stirred for 2 hours then cooled to 0" before gradually adding a solution of chloro-N-(2-phenylethyl)acetamide (3.7 g) in dimethylformamide and allowing the mixture to warm to room temperature. After stirring overnight the solvent was removed under reduced pressure and the residue taken up in ethyl acetate. The organic layer was washed with dilute aqueous hydrochloric acid and brine. Drying and evaporation of the solvent under reduced pressure gave a yellow oil which was purified by column chromatography (Sio 2 ) . Mass Spectrum: 339 (mono-TMS derivative) ; nmr δ (CDC1 3 ) 2.57 (t, 2H) , 2.69 (t, 2H) , 2.85 (m, 2H) , 3.22 (s, 2H) , 3.53-3.58 (q, 2H) , 7.14-7.34 (m, 6H) . b) N-r2- (2.4-Dimethoxy-l.3-benzothiazol-7-yl)ethyll-3- r2-oxo-2-f2-phenylethylamino)ethylthio propanamide Carbonyldiimidazole (3.04 g) was added to a solution of the compound from step a) (4.55 g) in dichloromethane (30 ml) and the mixture stirred at room temperature for 90 min. 2-(2,4-dimethoxy-l,3-benzothiazol-7-yl)-ethyla ine (4.06 g) in dichloromethane was added and the mixture stirred overnight. Water was then added and the aqueous phase extracted with dichloromethane. The organic extracts were washed (dilute HC1, NaHC0 3 and brine) , dried (MgS0 4 ) and the solvent removed under reduced pressure to yield the sub-titled compound as an orange oil which was used without further purification. Mass Spectrum: FAB 488 ((M+H) + ). c) N-r2-(4-Methoxy-2-oxo-3H-1.3-benzothiazol-7-yl)- ethyl]-3-.2-oxo-2-(2-phenylethylamino1ethylthiolpropanamide Cone, hydrochloric acid (sg. 1.18, 1.5 ml) was added to the compound from step b) (3.3 g) in methanol (30 ml) and the mixture stirred at roc temperature overnight. The solvent was evaporated under reduced pressure and the residue partitioned between chloroform and water. The organic layer was separated and the aqueous layer extracted with dichloromethane. The combined organic extracts were dried (MgS0 4 ) and the solvents removed under reduced pressure to give the sub-titled compound as an orange oil. Mass Spectrum: FAB 474 ((M+H) + ); nmr δ (CDC1 3 ) 2.38-3.77 (m, 14H) , 3.82-3.92 (m, 3H) , 6.27 (brs, IH) , 6.74 (d, IH) , 6.93 (d, IH) , 7.1 (brs, IH) , 7.15-7.33 (m, 5H) , 9.05 (s, IH) . d) N-r2-f4-Methoxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl1- -3-f2-oxo-2- ( 2-phenylethylamino)ethylsulphonyl1oropanamide Potassium peroxymonosulphate (5.57 g) was gradual added to a solution of the compound from step c) (2.81 g) in methanol:water (6:4, 72 ml) cooled to 0°. The mixture was stirred for 4 hours, water added and the whole extracted with chloroform. A yellow solid precipitated from the aqueous layer and was removed by filtration, and washed (water and pentane) to give the sub-titled compound. Mass Spectrum: FAB 506 ((M+H) + ); nmr δ (dgDMSO) 2.60-2.78 (2xt, 4H) , 3.24-3.39 ( , 4H) , 3.45-3.55 (m, 4H) , 3.84 (s, 3H) , 4.08 (s, 2H) , 6.92 (d, IH) , 6.96 (d, IH) , 7.18-7.32 (m, 5H) , 8.18 (brt, IH) , 8.44 (brt, IH) , 11.86 (s, IH) . e) 4-Methoxy-7-r2-N-r3-T2-N'-(2-Phenylethyl)aminoethyl]- sulphonyloropyl]aminoethyl1-1.3-benzothiazol-2.3H)-one dihvdrochloride Prepared by the method of Example lb) . Mass Spectrum: FAB 478 ((M+H) + ). f) 4-Hydroxy-7-r2-f3-r2-(2-phenylethyl)aminoethyl1- sulphonylpropyl1aminoethyl]-1.3-benzothiazol-2(3H)-one dihydrochloride The compound from step e) (0.33 g) was dissolved in 48% aqueous hydrobromie acid (10 ml) to which hypophosphorous acid (2 drops) had been added and the mixture heated to reflux under argon for 3 hours. The hydrobromie acid was removed under reduced pressure and the residue purified by reverse phase HPLC using methanol/0.1% aqueous trifluoroacetic acid as eluant, to give the title compound. mp 241-244" ; nmr δ (d g DMSO) 2.03-2.15 (m, 2H) , 2.86 (t, 2H) , 2.96 (t, 2H) , 3.02-3.18 (brm, 4H) , 3.22 (t, 2H) , 3.40-3.45 (m, 4H) , 3.62 (t, 2H) , 6.76 (d, IH) , 6.86 (d, IH) , 7.23-7.39 (m, 5H) , 8.93 (brs, 2H) , 9.16 (brs, 2H) , 10.11 (s, IH) , 11.76 (s, IH) ; Analysis: Found C,43.99; H,5.27; N,6.74; S,10.30% 22 H 2 9 N 3 ° 4 S 2* 1 * 8HC ^ requires: C,43. 8 8 ; H,5.49; N,6.98; S,10.64%. Example 6 -R.S)-4-Hvdroxy-7-r2-r7-(2-phenylethoxy)-hept-2-yl1- aminoethyl1-1.3-benzothiazol-2.3H)-one hydrochloride Sodium cyanoborohydride (0.056 g) , 6-(2-phenylethoxy- oxy)-heptan-2-one (1.450 g) and 6% aqueous acetic acid (20 drops) were added to a solution of 7-(2-aminoethyl)-4- hydroxy-l,3-benzothiazol-2(3H)-one hydrochloride (0.300 g) in methanol (30 ml) . The mixture was stirred for 4 days at room temperature until HPLC, using methanol/0.1% aqueous trifluoroacetate as eluant, revealed that all the starting material had been consumed. Aqueous ammonium hydroxide (2 drops) was added and the solvent removed under reduced pressure. Purification by chromatography (Si0 2 ) using ethanol/dichloromethane as eluant followed by reverse phase HPLC, using methanol/0.1% aqueous trifluoroacetate as eluant, and formation of the hydrochloride salt gave the title compound as a white solid. mp 166-168° ; Mass Spectrum: FAB 429 ((M+H) + ); nmr δ (dgDMSO) 1.20-1.40 (m, 5H) , 1.20 (d, 3H) , 1.40-1.60 (m, 2H) , 1.70 (brm, IH) , 2.79 (t, 2H) , 2.88 (m, 2H) , 3.00-3.20 (brm, 3H) , 3.37 (t, 2H) , 3.55 (t, 2H) , 6.76 (d, IH) , 6.89 (d, IH) , 7.15-7.30 (m, 5H) , 8.81 (brs, IH) , 8.90 (brs, IH) , 10.14 (s, IH) , 11.77 (S, IH) ; Analysis: Found C,61.45; H,7.67; N,6.17; S,7.06% C 2 H 32 N 0 3 S.HC1 requires: C,61.99; H,7.15; N,6.02; S,6.89%. Example 7 The following compound was prepared by the method of Example 6: (R.S)-4-Hvdroxy-7-r2-r3- (4-methoxyphenyl)propyl1- aminoethyl]-1.3-benzothiazol-2(3H)-one hydrochloride. mp 210" ; Mass Spectrum: FAB 359 ((M+H) + ); nmr δ (dgDMSO) 1. 10 (d, 3H) , 2 .58 ( q, IH) , 2 . 68 (brm, 2H) , 3 .4-3 . 5 (4H+H 2 0) , 3 .73 (S, 3H) , 6.76 (d, IH) , 6. 90 (d, 3H) , 7 . 16 (d, 2H) , 8 . 89 (brs , 2H) , 10. 13 (s , IH) , 11. 77 ( s , IH) ; Analysis: Found C,53.79; H,5.55; N,6.16% C 19 H 2 N 2 0 3 S.2HC1 requires: C,53.03; H,5.39; N,6.51%. Example 8 6-r2-r (4-Hydroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyl] amino1-N- (2-phenylethyl)hexanamide hydrochloride a) 6-fN'-(2-Chloro-4-methoxy-l.3-benzothiazol-7-yl)ethyl]■ N'-r (2 .2 .2-trifluoroacetyl)amino]-N- ( 2-phenylethyl)- hexanamide Sodium hydride (80% in oil, 0.244 g) was added to a stirred solution of N-[2-(2-chloro-4-hydroxy-l,3-benzo- thiazol-7-yl)ethyl]trifluoroacetamide (2.5 g) at room temperature. After stirring for 10 min the reaction was heated to 65° for 90 min. The mixture was cooled and a solution of 6-bromo-N-(2-phenylethyl)hexanamide (2.42 g) in dimethylformamide added, the mixture was stirred for 16 hours then heated to 70" for 3.5 hours. The solvent was evaporated under reduced pressure and the residue partitioned between dilute aqueous HCl and ethyl acetate. The organic layer was washed with brine, dried (MgS0 4 ) and the solvent removed under reduced pressure. Chromatography (Si0 2 ) using ethyl acetate/dichloromethane as eluant gave the sub-titled compound as a pale yellow oil. Mass Spectrum: FAB 556 ((M+H) + ); nmr δ (CDC1 3 ) 1.20-1.70 (m, 6H) , 2.05-2.18 ( , 2H) , 2.81 (t, 2H) , 2.87-3.07 (m, 2H) , 3.20+3.39 (2xt, 2H) , 3.49-3.56 (q, 2H) , 3.59-3.66 (m, 2H) , 4.01+4.02 (2xs, 3H) , 5.45 (brs, IH) , 6.89 {t, IH) , 7.15-7.34 (m, 6H) . b) 6-r2-T ( 2 .4-Dimethoxybenzothiazol-7-y1)ethyl1amino1-N- ( 2-phenylethyl)hexanamide The compound from step a) (1.73 g) in methanol was added to a solution of sodium methoxide in methanol (Na metal 0.17 g in methanol 40 ml). The mixture was heated under reflux for 4.5 hours, water (6 ml) was added and the mixture heated under reflux for a further 18 hours. The solvent was removed under reduced pressure, water added and the residue acidified with glacial acetic acid then made basic with ammonium hydroxide solution. The solution was extracted with chloroform, the organic layers dried (Na 2 S0 4 ) and the solvent removed under reduced pressure. Chromatography (Si0 2 ) using methanol/dichloromethane as eluant gave the sub-titled compound as a pale yellow solid. mp 112-113° ; Mass Spectrum: FAB 456 ((M+H) + ); nmr δ (CDC1 3 ) 1.23-1.33 (m, 2H) , 1.40-1.65 (m, 2H) , 2.11 (t, 2H) , 2.61 (t, 2H) , 2.84 (t, 2H) , 2.85-3.00 (m, 6H) , 3.50-3.57 (q, 2H) , 3.99 (s, 3H) , 4.24 (s, 3H) , 5.45 (brs, IH) , 6.82 (d, IH) , 7.02 (d, IH) , 7.17-7.3 (m, 5H); Analysis: Found C,66.25; H,7.38; N,9.39; S,6.82% C 25 H 3 3 N 3° 3 S requires: C,65.90; H,7.30; N,9.22; S,7.04%. c) 6-r2-f4-Hvdroxy-2-oxo-3H-1.3-benzothiazol-7-yl)ethyl- amino1-N-.2-phenylethyl)hexanamide hvdrochloride Boron tribro ide (1M in dichloromethane, 15 ml) was added dropwise to a solution of the compound from step b) (0.53 g) in dichloromethane (30 ml). The mixture was stirred at room temperature for 48 hours and a further portion of boron tribromide solution (7 ml) added. Stirring was continued for 24 hours, methanol added to destroy any remaining boron tribromide and the solvent removed under reduced pressure. A portion of toluene was added and then removed under reduced pressure. The residue was purified by reverse phase HPLC using methanol/0.1% aqueous trifluoroacetic acid as eluant. Conversion to the hydrochloride salt gave the title compound as a white solid. mp 206-208 Mass Spectrum: FAB 428 ((M+H) + ); nmr <S (dgDMSO) 1.20-1.30 (m, 2H) , 1.42-1.53 (q, 2H) , 1.50-1.65 (q, 2H) , 2.05 (t, 2H) , 2.70 (t, 2H) , 2.80-2.95 (m, 4H) , 3.00-3.12 (brm, 2H) , 3.22-3.31 (q, 2H) , 6.77 (d, IH) , 6.87 (d, IH) , 7.15-7.30 (m, 5H) , 7.92 (t, IH) , 8.87 (brs, 2H) , 10.15 (brs, IH) , 11.77 (s, IH) ; Analysis: Found C,54.71; H,6.08; N,8.22; S,5.88; Cl,12.34% C 23 H 29 N 3 0 3 S.2HC1 requires: C,55.19; H,6.24; N,8.40; S,6.41; Cl,14.16%. Example 9 4-Hydroxy-7-r2—f6-.2-phenylethylthio)hexyl1aminoethyl]■ 1.3-benzothiazol-2(3H)-one hydrochloride a) 6-(2-Phenylthio)hexanoic acid l- \ 2- \6-(2-phenylethyl- thio)hexana ido]ethyl]-1.3-benzothiazol-2.3H)-one ester Triethylamine (1 ml) was added to a suspension of 7-(2-aminoethyl)-4-hydroxy-l,3-benzothiazol-2(3H)-one hydrobromide (2.07 g) in chloroform (30 ml). Triethylamine (2 ml) followed by ethyl chloroformate (1.33 ml) were added to a solution of 6-(2-phenylethylthio)hexanoic aeid (3.35 g) in chloroform (30 ml) and the mixture stirred for 30 min. The two solutions were then mixed and stirred for 72 hours at room temperature. Water was added and the aqueous layer extracted with dichloromethane, the organic layers were washed with brine, dried (MgS0 4 ) and the solvent removed under reduced pressure. Chromatography (Si0 2 ) using methanol/dichloromethane as eluant gave the sub-titled compound as a white solid, mp 178-178.5°; Mass Spectrum: FAB 679 ((M+H) + ); nmr «S (CDC1 3 ) 1.23-1.29 (m, 2H) , 1.42-1.68 (m, 10H) , 1.99-2.04 (t, 2H) , 2.45-2.84 (m, 16H) , 3.27-3.33 (a, 2H) , 6.99 (S, 2H) , 7.18-7.30 (m, 10H) , 7.90-7.93 (t, IH) , 12.16 (s, IH) ; Analysis: Found C,65.65; H,7.02; N,4.17; S,13.71% C 3 7 H 4 6 N 2° 4 S 3 requires: C,65.48 ; H,6.78; N,4.12; S,14.15%. b) 4-Hydroxy-7-.2-T6-(2-phenylethylthio)hexyl1aminoethyl]- 1.3-benzothiazol-2 (3H)-one hydrochloride Prepared by the method of Example lb) using the compound from step a) . mp 226.5-227.5° ; nmr δ (dgDMSO) 1.25-1.4 (m, 4H) , 1.45-1.65 (m, 4H) , 2.7-2.95 (m, 8H) , 3.0-3.1 (m, 2H) , 3.34 (brs, 2H) , 6.75+6.88 (2xd, 2H) , 7.17-7.30 (m, 5H) , 8.84 (brs, 2H) , 10.14 (s, IH) , 11.77 (S, IH) ; Analysis: Found C,59.46; H,6.85; N,6.08; s,13.35% C 2 3 H 30 N 2°2 S 2* HC1 requires: C,59.14; H,6.69; N,6.00; S,13.73%. Example 10 N-r2-Hvdroxy-5- 2-N'-f6-(2-phenylethoxy)hexyl1amino¬ ethyllphenyllformamide oxalate salt a) N-f2-(3-Nitro-4-phenylmethoxyphenyl) thyll rifluoro¬ acetamide Benzyl bromide (7.86 g) was added to a stirred solution of N-[2-(3-nitro-4-phenol)ethyl]trifluoroacetamide (11.66 g) and anhydrous potassium carbonate (6.3 g) in dimethylformamide (100 ml) , cooled in an ice bath. Stirring was continued for 5 hours and the mixture poured into ice/water. The solid produced was dissolved in ethyl acetate and the aqueous phase extraced with ethyl acetate. The organic extracts were washed with brine, dried and the solvent removed under reduced pressure. The residue was purified by column chromatography to give the sub-titled compound as a white crystalline solid. mp 85-86° ; Mass Spectrum: Rbl 453/5 ((M+Rb) "f ); nmr δ (CDC1 3 ) 2.87 (t, 2H) , 3.58 ( , 2H) , 5.20 (S, 2H) , 6.56 (br, IH) , 7.07 (d, IH) , 7.3-7.5 (m, 6H) , 7.69 (d, IH) ; Analysis: Found C,55.95; H,4.28; N,7.63; F,15.98% C 1 7 H 1 5 F 3 N 2° 4 requires: C,55.43 ; H,4.10; N,7.65; F,15.47%. b) 3-Nitro-4-,phenylmethoxy)benzeneethanamine hydrochloride The compound from step a) (9.8 g), and anhydrous potassium carbonate (4.03 g) in water (10 ml) and ethanol (100 ml) were heated to reflux for 2 hours. The ethanol was evaporated under reduced pressure, water was added and the mixture extracted with ethyl acetate. The organic extracts were dried and the solvent removed under reduced pressure and the residue converted to the hydrochloride salt. mp 190-193°; Mass Spectrum: FAB 272 ((M+H) + ); nmr δ (d g DMSO) 2.92 (t, 2H) , 3.04 (t, 2H) , 5.30 (s, 2H) , 7.3-7.5 (m, 6H) , 7.57 (dd, IH) , 7.83 (d, IH) , 8.15 (brs, 3H) ; Analysis: Found C,56.68; H,5.43; N,8.84; Cl,11.14% C 15 H 1 6 N 2° 3* H __ requires: C,56.68; H,5.72; N,8.79; Cl,11.13%. c) N-2-f3-Nitro(4-phenylmethoxy) henyl1ethyl-6- ( 2- phenylethoxy)hexanamide Carbonyldiimidazole (0.33 g) was added to a solution of 6-(2-phenylethoxy)hexanoic acid (0.47 g) in dichloromethane, the mixture was stirred at room temperature for 1 hour. A solution of-the compound from step b) (0.54 g) was then added and the mixture stirred for 1 hour. Water was added and the organic layer separated and washed with dilute HC1 and brine, dried (MgS0 4 ) and the solvent removed under reduced pressure. The residue was purified by column chromatography. Mass Spectrum: FAB 491 ((M+H) + ); nmr <5 (CDC1 3 ) 1.33 (m, 2H) , 1.59 (m, 4H) , 2.1 (t. 2H) , 2 . 82/2 . 86 (t , 2x2H) , 3 . 41-3 . 61 (m, 3x2H) , 5 . 21 ( s , 2H) , 7 . 04 (d , IH) , 7 . 15-7 . 6 (m, 11H) , 7 . 66 (d, IH) . d) 3-Nitro-4-phenylmethoxy-N-r6-(2-phenyl thoxy)hexyl1- benzeneethanamine hydrochloride Prepared by the method of Example lb) using the compound from step c) . mp 142-143"; Mass Spectrum: FAB 477 ((M+H) + ); nmr <S(dgDMSO) 1.45 (brm, 4H) , 1.47 (brt, 2H) , 1.60 (brt, 2H) , 2.80 (t, 2H) , 2.85 (brm, 2H) , 3.00 (m, 2H) , 3.12 (brm, 2H) , 3.37 (t, 2H) , 3.55 (t, 2H) , 5.30 (s, 2H) , 7.15-7.45 (m, 11H) , 7.57 (dd, IH) , 7.84 (d, IH) , 8.97 (brs, 2H) ; Analysis: Found C,67.52; H,7.44; N,5.71; Cl,6.90% C 29 H 3 gN 2 0 4 .HCl requires: C,67.88; -H,7.27; N,5.46; Cl,6.91%. e) 3-Nitro-N-f6-(2-phenylethoxy)hexyl]-4-.phenylmethoxy)-N -(phenylmethoxycarbonyl)benzeneethanamine Triethylamine (0.165 g) was added to a stirred suspension of the compound from step d) (0.25 g) in dichloromethane (20 ml) cooled in ice. Benzylchloroformate (0.1 g) was added and the mixture allowed to warm to room temperature. The mixture was stirred until TLC indicated the reaction was complete then a further equivalent of benzylchloroformate was added and the mixture stirred for a 2 hours. Water was added, the organic layer was separated, dried and the solvent removed under reduced pressure to give the sub-titled compound as a yellow oil which was used without further purification. Mass Spectrum: TSP with NH 4 + 628 ((M+NH 4 ) + ); nmr <5 (CDC1 3 ) 1.28-1.52 (m, 6H) , 2.8-2.89 (m, 6H) , 3.17 (m, 2H) , 3.41 (m, 4H) , 3.60 (t, 2H) , 4.59 (s, 2H) , 5.07-5.20 (m, 2H) , 7.20-7.60 (m, 18H) . f) 3-Amino-4-(phenylmethoxy)-N-r6-(2-phenylethoxy)hexyl]- N-(phenylmethoxycarbonyl)benzeneethanamine Prepared by the method of Example 4b) , and the resulting oil purified by column chromatography (Si0 2 ) using diethyl ether:petrol (1:1) as eluant. Mass Spectrum: FAB 581 ((M+H) + ); nmr <S (CDC1 3 ) 1.25 (m, 4H) , 1.51 (m, 4H) , 2.70 (m, 2H) , 2.87 (t, 2H) , 3.17 (m, 2H) , 3.40 (m, 4H) , 3.60 (t, 2H) , 5.04 (m, 2H) , 5.12 (m, 2H) , 6.4-6.8 (m, 3H) , 7.15-7.50 (m, 15H) . g) N-5-r2-N'-r6-(2-Phenylethoxy)hexyl1aminoethyl1-N'- r (phenylmethoxycarbonyl)-2-(phenylmethoxy)phenyl]formamide The compound from step f) (0.58 g) was heated under reflux for 21 hours in neat ethylformate. The reaction was evaporated to dryness and the residual oil purified by column chromatography using ethyl acetate:petrol (1:3) as eluant. Mass Spectrum: FAB 609 ((M+H) + ); nmr δ (CDC1 3 ) 1.25 (m, 4H) , 1.51 (m, 4H) , 2.78 (m, 2H) , 2.87 (t, 2H) , 3.2-3.4 (m, 6H) , 3.6 (t, 2H) , 5.06 (s, 2H) , 5.12 (d, 2H) , 6.85 (m, 2H) , 7.15-7.45 (m, 16H) , 7.6-7.75 (brs, IH) , 8.26-8.38 (d, IH) . h) N-r2-Hvdroxy-5-f2-N'-.6-(2-phenylethoxy)hexyl1amino¬ ethyl]phenyllformamide oxalate salt A mixture of the compound from step g) (0.3 g), ammonium formate (0.3 g) and 10% Pd/C (0.3 g) in methanol (30 ml) was heated at reflux for 30 min. The mixture was filtered (Hyflo Supergel) and the solvent evaporated under reduced pressure. The resulting solid was purified by column chromatography (Si0 2 ) using dichloromethane:methanol (4:1) as eluant. The free base of the title compound was then converted to the oxalate salt, mp 207-209"; Mass Spectrum: FAB 385 ((M+H) + ); nmr δ (dgDMSO) 1.28 (m, 4H) , 1.47 (m, 2H) , 1.55 (m, 2H) , 2.79 (m, 4H) , 2.85 (m, 2H) , 3.00 (m, 2H) , 3.37-3.55 (m, 4H+H 2 0) , 6.82 (m, 2H) , 7.23 (m, 6H) , 7.99 (br, IH) , 8.27 (br, IH) , 8.6 (brs, 2H) , 9.6 (brs, IH) ; Analysis: Found C,57.94; H,6.93; N,6.02% C 2 3 H 32 N 2°3* C 2 H 2 0 4 ( °* 9M oxalate) requires: C,57.94; H,6.45; N,6.04%. Example 11 7-.2-r6-r2-(4-Aminophenyl)ethoxy]hexyl1 minoethyl1-4- hvdroxy-1.3-benzothiazol-2(3H)-one dihydrochloride a) N-T2-(4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)ethyll- 6-r2-(4-nitrophenyl)ethoxy1hexanamide Prepared by the method of Example la) , using 6-[2-(4-nitrophenyl)ethyl]hexanoic acid and 7-(2-aminoethyl)-4-hydroxy-l,3-benzothiazol-2(3H)-one hydrobromide. Mass Spectrum: FAB 474 ((M+H) + ); nmr δ (dgDMSO) 1.2 (m, 2H) , 1.45 (m, 4H) , 2.0 (t, 2H) , 2.55 (t, 2H) , 2.95 (t, 2H) , 3.25 (m, 2H) , 3.35 (t, 2H) , 3.62 (t, 2H) , 6.70 (d, IH) , 6.79 (d, IH) , 7.50-8.15 (m, 4H) ; Analysis: Found C,58.18; H,5.99; N,9.01; S,6.57% C 23 H 27 N 3 0gS requires: C,58.33; H,5.75; N,8.87; S,6.77%. b) 6- 2-(4-Aminophenyl)ethoxy]-N-r2-(4-hydroxy-2-oxo-3H- 1.3-benzothiazol-7-yl)ethyl]hexanamide The compound of step a) (0.5 g) , hydrazine hydrate (5 ml) and 10% Pd/C (0.05 g) in ethanol (50 ml) were heated at reflux for 2 hours. The mixture was filtered (Hyflo Supergel) , the solvent removed under reduced pressure and the residue purified by chromatography-using dichloromethane: methanol (9:1) as eluant. Mass Spectrum: FAB 444 ((M+H) + ); nmr δ (dgDMSO) 1.2 (m, 2H) , 1.45 (m, 4H) , 2.0 (t, 2H) , 2.6 (m, 4H) , 3.25 (m, 2H) , 3.3-3.45 (t, 2x2H) , 4.82 (brs, 2H) , 6.45-6.85 (dd, 4H) , 6.7-6.8 (dd, 2H) , 7.84 (t, IH) , 9.89 (brs, IH) , 11.6 (brs, IH) ; Analysis: Found C,62.45; H,6.70; N,9.64; S,6.76% C 23 H 29 N 3°4 S requires: C,62.28; H,6.59; N,9.47; S,7.22%. c) 7—r2— 6-,2-(4-Aminophenyl)ethoxylhexyl1aminoethyl]-4- hydroxy-1.3-benzothiazol-2(3H)-one dihvdrochloride Prepared by the method of Example lb) , using the compound from step b) . mp 154-157°; Mass Spectrum: FAB 430 ((M+H) + ); nmr δ (dgDMSO) 1.25 (m, 4H), 1.45 (m, 2H) , 1.58 (m, 2H) , 2.6-2.9 (m, 6H) , 3.05 (m, 2H) , 3.35 (t, 2H) , 3.55 (t, 2H) , 6.78-6.88 (dd, 2H) , 7.3 (m, 4H) , 9.05 (brs, 2H) , 10.15 (s, IH) , 10.3 (br, IH) , 11.8 (brs, IH) ; Analysis: Found C,53.80; H,6.64; N,8.22; Cl,13.77; S,5.82% C 23 H 31 N 3 O 3 S.2HCl(0.83M H 0) requires: C,53.38; H,6.75; N,8.12; Cl,13.70; S,6.19%. Example 12 4-Hvdroxy-7-r2-r6-T2-(2-pyridyl)ethoxy]hexyl]amino¬ ethyl]-l.3-benzothiazol-2(3H)-one oxalate salt A mixture of 4-Hydroxy-7-(2-aminoethyl)-1,3- benzothiazol-2(3H)-one (0.945 g) , 2-(6-bromohexyloxyethyl)- pyridine (0.863 g) and diisopropylethylamine (0.66 ml) in dry dimethylformamide (25 ml) was heated at 100° for 2.5 hours. The solvent was removed under reduced pressure and the residue purified by column chromatography (Si0 2 ) using dichloromethane:methanol (9:1) as eluant. The resulting free base was then converted to the title oxalate salt. mp 182-183° (decomposes); Mass Spectrum: FAB 416 ((M+H) + ); nmr δ (dgDMSO) 1.25 (m, 4H) , 1.50 (m, 4H) , 2.85 (m, 6H) , 3.1 (m, 2H) , 3.38 (m, 2H) , 3.65 (m, 2H) , 6.75-6.85 (dd, 2H) , 7.2 (dd, IH) , 7.35 (d, IH) , 7.70 (m, IH) , 8.45 (d, IH) , 8.70 (brs, IH) , 11.75 (brs, IH) ; Analysis: Found C,53.70; H,5.98; N,7.60; S,5.56% C 22 H 29 N 3 0 3 S. (0.5M H 2 0, 0.5M excess oxalic acid) requires: C,53.54; H,5.88; N,7.48; S,5.70%. Example 13 7.7'-r1.6-Hexanediylbis(imino-2.1-ethanediyl)bisr4- hvdroxy-1.3-benzothiazol-2(3H)-one difluoroacetate a) Bis-N.N'-f (2.4-dimethoxy-l.3-benzothiazol-7-yl)ethyl]- hexan-1.6-diamide Adipoyl chloride (1.15 g) in dichloromethane was added dropwise over 30 min to a stirred solution of 2-(2,4-dimethoxy-l,3-benzothiazol-7-yl)ethanamine (3.0 g, J. Med. Chem.. 1987, 3_0, 1166) and triethylamine (3.5 ml) in dichloromethane (150 ml) . The mixture was stirred at room temperature for 60 hours, filtered and the filtrate washed with dilute HC1, aqueous sodium bicarbonate and brine. The solvent was removed under reduced pressure and the residue stirred with dilute HCl. The solid was filtered, dissolved in chloroform, washed with brine, dried (MgS0 4 ) and the solvent removed under reduced pressure. Purification by chromatography (Si0 2 ) gave the sub-titled compound which was used without further purification in the next step. Mass Spectrum: FAB 587 ((M+H) + ). b) N.N'-r2-(2.4-dimethoxy-l.3-benzothiazol-7-yl)ethyl1-hex an-l.6-diamine dihydrochloride Prepared by the method of Example lb) using the compound from step a) . Mass Spectrum: FAB 559 ((M+H) + ). c) 7.7'-r1.6-Hexanediylbis(imino-2.1-ethanediyl)bisf4- hvdroxy-1.3-benzothiazol-2(3H)-one difluoroacetate The compound from step b) was dissolved in aqueous hydrobromie acid (48%) to which several drops of hypophosphorous acid had been added. The solution was refluxed for 3 hours. The solvent was removed under reduced pressure and the residue purified by preparative reverse phase HPLC to give the title compound. mp 231-233 ° ; Mass Spectrum: FAB 517 ((M+H) + ); nmr δ (dgDMSO) 1.32 (brs, 4H) , 1.58 (brs, 4H) , 2.83 (brt, 4H) , 2.93 (bt, 4H) , 3.10 (brt, 4H) , 6.74-6.90 (m, 4H) , 8.56 (brs, 2H) , 10.16 (s, 2H) , 11.76 (brs, 2H) ; Analysis: Found C,43.11; H,4.28; N,6.78; S,8.66% C 24 H 3 0 N 4°4 S 2 requires: C,43.11; H,3.97; N,6.77; S,7.75%. Example 14 7-r2-r1.l-Dimethyl-6-(2-phenylethoxy)hexyl1aminoethyl] ■ 4-hvdroxy-l.3-benzothiazol-2(3H)-one hydrochloride a) l.l-Dimethyl-6-(2-phenylethoxy)hexanamide hydrochloride Diphenylphosphoryl azide (6.81 g) was added to a stirred solution of 2,2-dimethyl-6-(2-phenylethoxy)hexanoic acid (6.13 g) and triethylamine (2.5 g) in toluene (100 ml) and the reaction stirred at 80° for 3 hours. The organic layer was washed with water and evaporated under reduced pressure to give a yellow oil. The residue was taken up in dioxan (100 ml) , diluted with water (50 ml) , and acidified to pH 1 with cone, hydrochloric acid. The solution was heated on a steam bath for 3 hours, heated under reflux for 30 min and the solvent evaporated under reduced pressure. The residue was dried by azeotropic distillation with 2-propanol and recrystallised from petroleum ether 60-80°:ethyl acetate, mp 111-112°; Mass Spectrum: FAB 250 ((M+H) + ); - nmr δ (CDC1 3 ) 1.37-1.40 (brm, 4H) , 1.40 (s, 6H) , 1.54-1.61 (quin, 2H) , 1.67-1.69 (brm, 2H) , 2.85-2.89 (t, 2H) , 3.39-3.42 (t, 2H) , 3.58-3.62 (t, 2H) , 7.17-7.30 (m, 5H) , 8.33 (brs, 3H) ; Analysis: Found C,67.20; H,9.86; N,5.13; Cl,12.79% C 16 H 27 N0.HC1 requires: C,67.22; H,9.87; N,4.90; Cl,12.40%. b) (2.4-Dimethoxy-l.3-benzothiazol-7-yl)acetic acid A solution of (2,4-Dimethoxy-l,3-benzothiazol-7-yl)- acetonitrile (3.61 g, J. Med. Chem.. 1987, 3_0, 1166) and potassium hydroxide (3.45 g) in methanol:water (2:1, 150 ml) was heated to reflux for 6.5 hours. The reaction was cooled and the solvents evaporated under reduced pressure. Water (50 ml) was added and the aqueous layer extracted with diethyl ether. The aqueous layer was then acidified to pH4/5 with acetic acid and extracted with ethyl acetate. The combined organic layers were washed (water and brine) , dried (MgS0 4 ) and the solvent evaporated under reduced pressure to yield the sub-titled compound which was used in the next step without further purification. c) (4-Hydroxy-2(3H)-oxo-1.3-benzothiazol-7-yl)acetic acid Prepared by the method of Example 14c) using the compound from step b) . mp 170-175"; Mass Spectrum: 225 ((M+H) + ); nmr δ (dgDMSO) 3.47 (s, 2H) , 6.71 (d, IH) , 6.86 (d, IH) , 10.02 (brs, IH) , 11.68 (brs, IH) , 12.44 (brs, IH) ; Analysis: Found C,48.07; H,3.23; N,6.13; S,13.90% C 9 H 7 N0 4 S requires: C,47.99; H,3.13; N,6.22; S,14.20%, d) 2-(4-Hvdroxy-2-oxo-3H-l.3-benzothiazol-7-yl)-N-r1.1- dimethyl- \6-(2-phenylethoxy) 1hexyl1acetamide Prepared by the method of Example la) using the compounds from steps a) and c) . Mass Spectrum: Thermal Spray Plasma 457 ((M+H) + ); nmr δ (CDC1 3 ) 1.20-1.80 (m, 8H) , 1.38 (s, 6H) , 2.90 (S, 2H) , 3.42 (s, 2H) , 3.46 (t, 2H) , 3.66 (t, 2H) , 5.70 (s, IH) , 6.40 (d, IH) , 6.70 (d, IH) , 7.20-7.30 (m, 5H) , 8.77 (s, IH) . e) 7-r2-f1.l-Dimethyl-6-(2-phenylethoxy)hexyl1 minoethyl]- 4-hydroxγ-l.3-benzothiazol-2(3H)-one hydrochloride Prepared by the method of Example lb) using the compound from step d) . mp 183-185° ; Mass Spectrum: FAB 443 ((M+H) + ); nmr δ (dgDMSO) 1.25 (brs, 10H) , 1.45-1.60 (m, 4H) , 2.79 (t, 2H) , 2.90 (m, 2H) , 3.00 (brs, 2H) , 3.40 (m, 2H+H 2 0) , 3.56 (t, 2H) , 6.76-6.92 (d, 2H) , 7.2-7.3 (m, 5H) , 8.79 (s, 2H) , 10.13 (s, IH) , 11.77 (s, IH) ; Analysis: Found C,61.09; H,7.84; N,5.70; S,5.69% C 25 H 34 N 2 0 3 S.HC1 (12% ethanol) requires: C, 61.40; H,7.87; N,5.11; S,5.89%.

Claims: Claims: 1. Compounds of formula I, Ar-CH 2 CH 2 -NH-CR^-R 2 -X-Y in which Ar represents a group. X represents a C 1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from -S-, -SO-, -S0 2 -, -O-, CR 6 R 7 , phenylmethyne, -NH-, -CONH-, -NHCO- and -NHC0NH-, Y represents an optionally substituted aryl or cycloalkyl group, R 5 , _ 6 , R 7 and R 8 each independently represent hydrogen or alkyl C^g, and R 3 and R 4 represent hydrogen, or R 3 and R 4 together form a group -S-, -NR 8 - or -CH 2 -, and pharmaceutically acceptable derivatives thereof. 2. A compound of formula I, as defined in Claim 1, wherein R 3 and R 4 together represent the group -S-. 3. A compound of formula I as defined in Claim 1 or Claim 2, wherein R 5 represents hydrogen. 4. A compound of formula I as defined in any one of the preceding claims, wherein the -OH is positioned ortho to the NH in the Ar group. 5. A compound of formula I as defined in any one of the preceding claims, wherein Y represents- a 5- or 6- membered carbocyclic or heteroeyclic group optionally substituted by one or more groups selected from -OH, halogen, alkyl C 1 _ 6 , alkoxy C^g, =0, -NH 2 , or N0 2 . 6. A compound as defined in Claim 5, wherein Y represents phenyl optionally substituted by one or more groups selected from -OH, halogen, alkyl C 1-6 , alkoxy C 1 _ 6 , =0, -NH 2 , or N0 2 . 7. A compound of formula I which is 7-[2-[6-[2-(2,3-Dihydro-lH-indenyloxy) ]hexyl]amino¬ ethyl]-4-hydroxy-1,3-benzthiazol-2(3H)-one 4-Hydroxy-7-[2-[6-(2-phenylethoxy)hexyl]aminoethyl]- l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[5-(3-phenylpropoxy)pentyl]aminoethyl]- l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[5-[2-(5-methylfuranyl) ]pentyl]- aminoethyl]-l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[7-(2-phenylethoxy)heptyl]aminoethyl]- 1,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[4-(2-phenylethoxy)butyl]aminoethyl]- 1,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[5-(2-phenylethoxy)pentyl]aminoethyl]- l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[6-(phenylmethoxy)hexyl]aminoethyl]- l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[4-(4-phenylbutoxy)butyl]aminoethyl]- l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-(6-phenoxyhexyl)aminoethyl]-1,3- benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[6-(3-phenylpropoxy)hexyl]aminoethyl]- l,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[2-(4-methoxyphenyl)ethyl]aminoethyl]- 1,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[2,2-dimethyl-6-(2-phenylethoxy)hexyl]- aminoethyl]-1,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[6-(2-phenylethylsulphonyl)hexyl]amino¬ ethyl]-l,3-benzothiazol-2(3H)-one N-[6-[2-(4-Hydroxy-2-oxo-3H-l,3-benzothiazol-7-yl)- ethylaminoJhexyl]-N•-phenyl urea 4-Hydroxy-7-[2-[6-[2-(4-nitrophenyl)ethoxy]hexyl]amino¬ ethyl]-1,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[6-[2-(4-hydroxyphenyl)ethoxy]-2,2- dimethylhexyl]aminoethyl]-l,3-benzothiazol-2(3H)-one 7-Hydroxy-4-[2-[6-[2-(1-naphthyl)ethoxy]hexyl]amino¬ ethyl]-1,3-benzothiazol-2(3H)-one 7-[2-[6-(2-Cyclohexylethoxy)hexyl]aminoethyl]-4-hydroxy -1,3-benzothiazol-2(3H)-one 7-[2-[6-[2-(4-Bromophenyl)ethoxy]hexyl]aminoethyl]-4- hydroxγ-1,3-benzothiazol-2(3H)-one 4-Hydroxγ-7-[2-[6-[2-(2-thienyl)ethoxy]hexyl]amino¬ ethyl]-1,3-benzothiazol-2(3H)-one (R,S)-4-Hydroxy-7-[2-[2-methyl-6-(2-phenylethoxy)hexyl] -aminoethyl]-1,3-benzothiazol-2(3H)-one 1,3-Dihydro-4-hydroxy-7-[2-[6-(2-phenylethoxy)hexyl]- aminoethyl]-2H-benzimidazol-2-one 4-Hydroxy-7-[2-[6-[2-(4-hydroxyphenyl)ethoxy]hexyl]- aminoethyl]-l,3-benzothiazol-2(3H)-one 2,3-Dihydro-7-hydroxy-4-[2-[6-(phenylethoxy)hexyl]- aminoethyl]-indol-2-one 4-Hydroxy-7-[2-[3-[2-(2-phenylethyl)aminoethyl]- sulphonylpropyl]aminoethyl]-1,3-benzothiazol-2(3H)-one (R,S)-4-Hydroxy-7-[2-[7-(2-phenylethoxy)-hept-2-yl]- aminoethyl]-1,3-benzothiazol-2(3H)-one ( ,S)-4-Hydroxy-7-[2-[3-(4-methoxyphenyl)propyl]- aminoethyl]-1,3-benzothiazol-2(3H)-one 6-[2-[(4-Hydroxy-2-σxo-3H-l,3-benzothiazol-7-yl)ethyl]- a ino]-N-(2-phenylethyl)hexanamide 4-Hydroxy-7-[2-[6-(2-phenylethylthio)hexyl]aminoethyl]- 1,3-benzothiazol-2(3H)-one N-[2-Hydroxy-5-[2-N'-[6-(2-phenylethoxy)hexyl]amino¬ ethyl]phenyl]formamide 7-[2-[6-[2-(4-Aminophenyl)ethoxy]hexyl]aminoethyl}-4- hydroxy-1,3-benzothiazol-2(3H)-one 4-Hydroxy-7-[2-[6-[2-(2-pyridyl)ethoxy]hexyl]amino¬ ethyl]-1,3-benzothiazol-2(3H)-one 7,7•-(1,6-Hexanediylbis(imino-2,1-ethanediyl)bis[4- hydroxy-1,3-benzothiazol-2(3H)-one] 7-[2-[1,l-Dimethyl-6-(2-phenylethoxy)hexyl]aminoethyl]■ 4-hydroxy-l,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable derivative of any one thereof. 8. A pharmaceutical composition comprising a compound of formula I, as defined in any one of the preceding Claims, or a pharmaceutically acceptable derivative thereof, in association with a pharmaceutically acceptable carrier, diluent or adjuvant. 9. A method for the preparation of a compound of formula I, as defined in any one of the preceding Claims, or a pharmaceutically acceptable derivative thereof, which comprises a) alkylation of a compound of formula II, or a derivative thereof, Ar-CH 2 CH 2 -NH 2 II in which Ar is as defined in Claim 1, with an alkylating agent of formula III, in which R 1 , R 2 , X and Y are as defined in Claim 1 and L represents a leaving group, b) alkylation of a compound of formula II, as defined in Claim 1, with a compound of formula IV, 0=CR 1 -X-Y IV in which R 1 , X and Y are as defined in Claim 1, in the presence of a reducing agent, c) selective reduction of a compound of formula V, Ar-CH 2 -C-NH-CR 1 R 2 -X-Y V in which Ar, X, Y, R 1 and R 2 are as defined in Claim 1, or for the production of compounds of formula I in which R 1 and R 2 represent hydrogen, selective reduction of a compound of formula Va, 0 Ar-CH 2 CH 2 -NH-C-X-Y Va in which Ar, X and Y are as defined in Claim 1, d) removal of a protecting group from a corresponding protected compound of formula I in which one or more of the functional groups is protected, and where desired or necessary converting a compound of formula I, or another derivative thereof, to a pharmaceutically acceptable derivative thereof or vice versa. 10. Compounds of formula Va, O II Ar-CH 2 CH 2 -NH-C-X-Y Va in which Ar, X and Y are as defined in Claim 1.

Inventors: BONNERT ROGER VICTOR, BROWN ROGER CHARLES, CHESHIRE DAVID RAYULS, DIXON JOHN, INCE FRANCIS, BONNERT, ROGER, VICTOR, BROWN, ROGER, CHARLES, CHESHIRE, DAVID, RAYULS, DIXON, JOHN, INCE, FRANCIS
Applicants: FISONS PLC
Application year: 1991
Main classification: C07D235
IPC codes: A61K31, A61P9, A61P17, A61P37, C07C233, C07C275, C07C317, C07C323, C07D209, C07D235, C07D277, C07D317, C07D417